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Abstract
The conventional coating of pharmaceutical pellets is achieved by liquid-based coating
techniques using a fluidized bed or a pan coater. However, many restrictions and
drawbacks such as long processing time and large energy consumption exist in the above
method. Dry powder coating technique is a novel solventless coating technique that is
able to mitigate the problems of liquid-based coating. In this study, a newly invented
coating apparatus called rotary fluidized bed (RFB), was applied for the coating of
pharmaceutical pellets by a dry powder coating process. The RFB has a unique structure
where the hot fluidizing air is further aided by the rotation to ensure a uniform coating.
Results of SEM micrographs indicated the piroxicam pellets formed continuous and
dense coating film in the RFB. In-vitro drug release tests confirmed that the dry powder
coated pellets successfully achieved immediate release, sustained release and delayed
release with Eudragit® EPO, Eudragit® RS/RL and Acryl-EZE, respectively. The optimal
operation conditions were as follows: curing temperature 2 h, curing temperature 50 oC,
RFB rotating speed ~20 rpm, liquid plasticizer spraying rate ~0.25 g/min and fluidizing
air flowrate ~35 L/min. The RFB demonstrated a comparable film formation quality and
coating efficiency with the pan coater, while superior to the fluidized bed. For the more
difficult-to-coat micronized pellets (0.1-0.3mm), the RFB presented better applicable
potential than the other two apparatus. In conclusion, the RFB is a promising dry powder
coating apparatus for pharmaceutical pellets coating.
Keywords: pellets coating, dry powder coating, rotary fluidized bed, drug release, fast
release, sustained release, delayed release, Eudragit® EPO, Eudragit® RS/RL, Acryl-EZE
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1.

Chapter 1
Introduction

1.1. Pharmaceutical coating
In the pharmaceutical coating industry, the coating of solid dosage forms are applied for
different purposes such as immediate release, sustained release and delayed release.
Among then, immediate release is essentially aimed at taste masking, easy identification
by the color of coating, protection of the active pharmaceutical ingredient (API) from
damage by the environment and so on. Sustained release allows the API to release over
an extended period of time that prolongs the therapeutic effect. Delayed release is to
release the API at a time instead of release immediately after oral administration. All the
above-mentioned purposes can be achieved with different coating materials.
Among the present coating techniques, liquid-based coating is the most common one for
coating of both large dosage forms such as tablets and small dosage forms such as pellets.
The liquid-based coating consists of organic solvent coating and aqueous coating. The
coating materials are dissolved/dispersed in the organic solvent/water, followed by being
sprayed onto the surface of the solid dosage forms, and a continuous coating film is
achieved with the evaporation of the organic solvent/water. Conventional Pellets coating
is usually accomplished by a fluidized bed or a pan coater.
However, the liquid-based coating of pellets has many restrictions and drawbacks. As for
organic solvent coating, the usage of the organic solvent may come with toxicity and
inflammability, which definitely brings potential hazards. For aqueous coating, it is not
appropriate for the moisture sensitive API. Besides that, the pellets tend to agglomerate
easily due to their relatively large specific area and small particle size, which leads to a
non-ideal coating. Moreover, both the organic solvent coating and aqueous coating
require large amounts of hot fluidizing air to maintain the constant temperature of the
1

coating system, and to evaporate the organic solvent and water. These not only result in
energy consumption but also long processing time.
To overcome the above-mentioned problems, a lot of endeavor has been done to improve
the technique of pellet coating. Many solventless coating techniques have been designed
to avoid the use of organic solvent and water, which significantly overcome the major
drawbacks of the liquid-based coating. Dry powder coating is one of the novel solventless
coating techniques that have drawn great attention in the pharmaceutical industry. The
dry powder coating of small dosage forms such as pellets and particles can be applied in a
rotating pan coater and a fluidized bed coater. The coated pellets have been shown to
achieve immediate release, sustained release and delayed release successfully. However,
limitations still exist with these two apparatuses. For the fluidized bed, a large amount of
hot fluidizing air is required to maintain stable fluidization of pellets and constant
temperature in the system. The agglomeration is an inevitable problem that usually
happens in a fluidized bed system. In terms of the rotating pan coater, when the solid
dosage forms have a relatively small size and weight, it is difficult to handle.
A novel apparatus called rotary fluidized bed (RFB) has been designed for the
pharmaceutical pellets coating using dry powder coating technique. The RFB has a
unique structure that introduces a small amount of fluidizing air in the coating system.
The fluidizing air can efficiently work together with a rotation action to prevent the
agglomeration of the pellets during the coating process. In comparison to the organic
solvent coating, it is more environmentally friendly since no toxic organic solvent is
required. In addition, the processing time and the temperature can be reduced
dramatically in contrast to the aqueous coating. This project is aiming to investigate pellet
coating using the RFB with dry powder coating technique.

2

1.2. Objectives
The main objective of this project is to investigate the application of the RFB in pellets
coating using dry powder coating technique, including the following parts:
Firstly, to realize immediate release, sustained release and delayed release with the dry
powder coated piroxicam pellets using Eudragit® EPO, Eudragit® RS/RL and Acryl-EZE
as the coating materials, respetively.
Secondly, to optimize the process conditions of pellets coating in regarding to curing time,
curing temprature, RFB rotating speed, plasticizer spraying flowrate and fluidizing air
flowrate.
Finally, to compare the operation conditions and the performance of the coated pellets in
the RFB with the other two typical coating apparatus, the rotating pan coater and the
traditional fluidized bed.

3

2.

Chapter 2
Literature Review

2.1. Types of drug release
Drug release profiles can be divided into the following types: immediate release, delayed
release and sustained release. Different release types have their unique release profile.
Figure 2.1 shows the typical drug release profiles of the three release types. The
modifications of the drug usually aim at the stability and safety improvement as well as
the therapeutic profile and efficiency enhancement.

Figure 2.1 Different types of drug release profiles

2.1.1. Immediate release
This type of release is commonly applied in pharmaceutical coating industry today, and is
aiming at a rapid dissolution of drug after oral administration, which means to get the
active pharmaceutical ingredient (API) into the blood stream and take action to the site as
quickly as possible. Usually, the fast release coated drug release to 100% within 30 min.
Reasons for immediate release coating are as follows: unpleasant taste or odor masking,
easy identification, drug protection, etc. Water-soluble polymers are usually served as the
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coating materials in the immediate release coating.

2.1.2. Sustained release
Sustained release, which is also called extended release, refers to the system that allows
drug to be released over an extended period of time to achieve prolonged therapeutic
effect after oral administration[1]. Based on the different goals of drug delivery, the
length of the sustained release time varies from 8-10 hours to 24 hours. Usually, this type
of coating is achieved by the coating of water-insoluble polymers.
The most obvious characterizations of this type are: first of all, the plasma concentration
can be maintained at a therapeutic range in the blood, which reduces the irritation in the
gastrointestinal tract and avoid the side effect of the drug. Second, the dosing frequency
can be decreased from dosing immediate release drug several times a day to only once a
day by dosing sustained release drug.

2.1.3. Delayed release
The definition of delayed release is the system formulated to release the active
pharmaceutical ingredient (API) at a time instead of release immediately after oral
administration[1]. The disintegration site of delayed release coated solid dosage forms
can be a specific region of the intestinal tract. The drug is considered to stay in the
stomach for about 2 h and pass to intestinal tract after the first 2 h. The coating polymers
that are used for reaching the above aim will dissolve as the pH changes, which means
the API will begin to release when the solid dosage forms move from the low-pH
environment (stomach) to the high-pH environment (intestinal tract). And once the
dosage forms reach the high-pH environment, the release profile is similar to the
immediate release.
The coating of delayed release is required due to the following reasons: firstly, to prevent
the drug from irritating the stomach; secondly, to protect the API from degradation under
5

the low pH environment of the stomach; finally, to target the drug absorption to a place
along the intestinal tract beyond the stomach.

2.2. Controlled Drug Release Mechanism
The controlled drug release mechanism of the previous mentioned three typical drug
release types can be divided into two systems, diffusion controlled drug release system
and erosion/degradation controlled drug release system. The mechanism was introduced
by Wnek and Bowlin detailedly[1].

2.2.1. Diffusion-controlled drug release system
Diffusion is defined as the action of drug molecules when stimulated by the change of
external environment[2]. Diffusion-controlled drug release systems can be classified into
two kinds: matrix system (monolithic system) and reservoir system (core-shell system).
In matrix system that is also called monolithic system, the API composes with a polymer
to form a matrix structure, and this special structure will react as a swelling phenomenon.
The swelling phenomenon is a uniform expansion of the composite matrix, which leads
to the appearance of opening pores that occupied the whole structure. The size of the
opening pores has to be much greater than the API molecule so that the diffusion can take
place. The diffusion of the drug from the polymer controls the release rate. As the release
time increases, the drug release rate decreases.
In the reservoir system that is also named core-shell system, the drug core is encapsulated
in a polymer membrane, and is released driven by the difference between the drug and
the surrounding environment[3]. Because the reservoir is coated with a permeable
polymer, when worked with water, the drug can diffuse through the membrane;
meanwhile, the outside water can swell the reservoir structure. Therefore, it is obviously
that the swelling phenomenon is not as uniform as the matrix structure dose. Also, the
pore size of the reservoir structure has to be greater than the drug molecule for the
6

purpose of effective diffusion. Furthermore, the diffusion drug release is dominated by
the rate of the diffusion through a water-insoluble barrier.

2.2.2. Degradation/ Erosion-controlled drug release system
In degradation/erosion controlled drug release system, basically, the drug and polymer
are combined either in the physical form or chemical form. In the physical form, the drug
is encapsulated in the polymer matrix, and releases in response to the erosion of the
polymer mass. In the chemical form, the drug attached to the chains of polymer, which
generates chemical bond between the drug and the polymer. When the chemical bond
breaks, the drug release starts.
Furthermore, the drug degradation can be classified into two categories depended on the
drug erosion location, which are bulk erosion and surface erosion[4]. In bulk erosion, as
the solution penetrates throughout the entire polymer matrix, the polymer composite will
degrade uniformly, which means the volume of the polymer composite remains constant
while the density decreases. On the contrary, when it comes to surface erosion, usually,
the polymer used in the matrix is hydrophobic, and thus the erosion will firstly take place
on the surface when interface with solution. Obviously, for the case of surface erosion,
the density of the polymer matrix remains constant while the volume decreases.

7

2.3. Coating materials
As mentioned above, the coating film, depending on the special aspects of use, works
either for protection or functional control. Reasons for applying coating are: taste
masking, light and moisture protection, appearance improvement, mechanical resistance
enhancement and drug release modification. Generally, the most commonly used
materials in the coating of solid dosage forms are semi-synthetic copolymers of cellulose
derivatives and synthetic methacrylate polymers. By changing the functional groups or
mechanical properties of the polymers, the coating film is able to modulate different
types of drug release profiles[2].

2.3.1. Polymers for immediate release
The coating polymers aiming at immediate release are mostly water-soluble polymers,
which are able to dissolve immediately to guarantee fast release without postponement.
Today, most common employed immediate release polymers are cellulose ethers such as
hydroxypropyl methylcellulose (HPMC, shown in Figure 2.2), and methacrylate-based
polymer developed by Evonik (trade name: Eudragit® E).

Figure 2.2 Hydroxypropyl methylcellulose molecular structure
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HPMC has a very good solubility not only in water but also in organic solvent and is
commonly used from the coating of early days. Furthermore, apart from of being the
immediate release polymer, HPMC can also work as porogenic agent in the sustained
release formulations[1].

®

Figure 2.3 Eudragit E monomer structure

Eudragit® E, as shown in Figure 2.3, is a cationic copolymer, which is comprised of
dimethyl-laminoethyl methacrylate, butyl methacrylate and methyl methacrylate with a
ratio of 2:1:1. Eudragit® E has three forms of availabilities, which are named as Eudragit®
E100 (granules), Eudragit® E12, 5 (organic solution) and Eudragit® EPO (powder),
respectively. This type of polymer is able to dissolve in gastric solutions up to pH5.5,
which implies that it is insoluble in saliva, but will dissolve in stomach rapidly[3].

2.3.2. Polymers for sustained release
As mentioned above, polymers employed in sustained release (extended release) are
usually insoluble in water and independent from pH along the gastrointestinal tract,
which effectively increase the therapeutic effect and compliance of patient[4]. Commonly
used polymers for such purposes are ethyl cellulose (EC, shown in Figure 2.4) and
Eudragit® RL and Eudragit® RS (shown in Figure 2.5) developed by Evonik.

9

Figure 2.5 Ethyl cellulose molecular structure

EC, also named Aquacoat ECD and Ethocel in industry, is permeable in water in the
environment of GI tract, which assures the control of release rate. During the coating
process, liquid plasticizers are required for EC in order to form a coating film due to its
high glass transition temperature (Tg=133oC) [4].

®

®

Figure 2.4 Chemical structure of Eudragit RL and Eudragit RS

Eudragit® RL and Eudragit® RS (shown in Figure 2.5) are comprised of ethyl acrylate,
methyl methacrylate and a small amount of methacrylic acid ester with quaternary
ammonium groups (trimethyl-ammonioethyl methacrylate chloride) that serves as salts to
assure the permeability of the coating film. Those quaternary ammonium groups will be
ionized when contact with solution. This will lead to the swelling and opening pores of
the coating film. The only difference between the two polymers is the content of
quaternary ammonium groups. In Eudragit® RL, the molar ratio between the quaternary
10

ammonium groups to neutral methacrylic acid ester groups is 1:20, while this ratio is 1:40
of Eudragit® RS. Obviously, Eudragit® RL has double content of quaternary ammonium
groups compared to Eudragit® RS and thus has a higher permeability. Different drug
release rates can be obtained through adjusting the thickness of the coating film and
changing the ratio of the two polymers in the formulation[5].

2.3.3. Polymers for delayed release
Polymers employed in delayed (enteric) coating are equipped with the ability of
protecting the API from being damaged in the acid environment of gastrointestinal (GI)
tract. Meanwhile, these polymers have to dissolve easily when travelling to the small
intestine that has higher pH value. Similarly to immediate release, the most common
polymers served for delayed release coating are cellulose-based and methacrylate-based
polymers.

Figure 2.6 Cellulose acetate phthalate molecular structure

In the early age of delayed release coating, shellac was one of the earliest natural
polymers to meet this requirement[6]. Later on, cellulose acetate phthalate (CAP, shown
in Figure 2.6), a synthetic cellulose-based polymer has become a popular semi-synthetic
enteric coating material since it has a good performance of acid resistance and high
solubility in intestine environment of pH 6.0 to 6.4[7].
11

®

Figure 2.7 Chemical structure of A) Eudragit L 100-55,
®

®

B) Eudragit L 100 C) Eudragit S 100

At present, Evonik, a German company focused on specialty chemicals, has developed
several polymers for the enteric coating. The polymers are either in the form of organic
solution or powder. Among the above-mentioned products, Eudragit® L100-55,
Eudragit® L100 and Eudragit

®

S100 (shown in Figure 2.7) are three powder form

polymers that perform differently in the dissolution property based on the pH value
Eudragit® L100-55, also known as Acryl-EZE MP, is applied for the first section of the
small intestine-duodenum, and is able to dissolve in the media with pH above 5.5.
Eudragit® L 100 is aiming at delivery the drug to the middle part of small intestinejejunum, and thus is soluble in pH higher than 6.0. Eudragit® S is used for targeting the
drug to the last part of the small intestine, i.e. ileum, and dissolves in pH above 7.0.
Particularly, in terms of the molecular structure of the enteric polymers, most of them
contain carboxylic acid groups, which assure the strong protection of the API under low
pH circumstance.

2.3.4. Plasticizers
In the pharmaceutical coating industry, polymers applied for coating usually form brittle
films, and thus fail to modulate the desired drug release profiles[8]. With the addition of
plasticizers, the above-mentioned problem can be improved Usually, plasticizers are
water-insoluble materials with low molecular weight (200-1000) and high boiling point at
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room temperature[9]. Among the polymers, triethyl citrate (TEC) and polyethylene
glycol 400 (PEG400) are two typical plasticizers that are widely used in the
pharmaceutical coating industry. Particularly, TEC is a suitable plasticizer for Eudragit®
RL and Eudragit® RS, and PEG400 is appropriate for Eudragit® EPO and
Acryl-EZE[10-12].
Plasticizers are functionalized by incorporating themselves between/in the polymer
chains, increasing the free volume, so as to decrease the glass transition temperature (Tg)
of the polymers, improve the film flexibility and control the drug release[12-14]. By
applying a suitable amount of plasticizer, the plasticizer will first stay on the surface of
the solid dosage forms before being absorbed, which actually enhance the capillary force
between the coating polymers and the surface of the solid dosage forms. Therefore, the
coating efficiency is enhanced[15, 16]. Moreover, in electrostatic dry coating technique,
plasticizers also play an important role in increasing the electrical conductivity,
improving the deposition of the coating materials on the solid dosage forms[10, 11, 17].
The selection of an appropriate plasticizer for a certain coating polymer is of great
importance in the coating process. Key factors are as follows: one is the spreading
behavior of the plasticizer, and the other is the application amount and the compatibility
between the plasticizer and coating polymer. Specifically, the spreading behavior can be
characterized by measuring the contact angle of the plasticizer on the coating film and
estimating the surface energy of the coating polymer. Viscosity data can give potential
information of the plasticizing activity[18]. Moreover, the solubility of the coating
polymer in the plasticizer can help to meet the requirement of a good compatibility[9, 19].
The applied amount of the plasticizers is another key factor in order to form a continuous
coating film[20]. Excessive amount of plasticizer may cause sticking problems while not
enough amount may lead to brittle coating film. As a result of this, looking for
the suitable amount of plasticizer becomes a critical condition for a coating process[8, 21].
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2.4. Solvent-based coating processes
In modern pharmaceutical coating processes, the solvent-based coating methods are
widely used, which includes sugar coating, organic solvent coating and aqueous coating.
The sugar coating was first invented in the 19th century[1]. After several decades, the
organic solvent coating technique appeared in 1930s and began to take place of the sugar
coating in 1950s. Aqueous film coating then replaced part of organic solvent coating
owing to its more environmental-friendly properties[22].

2.4.1. Sugar coating
The main principle of sugar coating is masking the bitter flavor of the drug, and
sacharose is one of the commonly used sugars in this coating method. The process
consists of four basic steps: sealing, subcoating, syruping and polishing.
Sugar coating has many restrictions and drawbacks. One major disadvantage is its long
processing time. Under some conditions, it can take up to 5 days to finish the sugar
coating process. What’s more, difficulties in the standardization of coating procedures
and the strict demand of high-level operators also indicate the complexity of the
operating conditions. Another disadvantage is the possibility of the breedly bacteria and
mold. This happens not only during the storage period, but also in each coating
procedure[1].

2.4.2. Organic solvent coating
The appearance of organic solvent coating decreases the long processing time
dramatically and overcomes the difficulty in complex operations compared to sugar
coating. Actually, this technique came out in 1930 but not commercialized until 1954 by
Abbott Laboratories. Figure 2.8 shows the schematic of organic solvent film coating
process, wherein the coating materials are dissolved in the organic solvent to form a
solution The solution is sprayed through a nozzle onto the solid dosage forms. Heat is
14

required in the following curing procedure to evaporate the organic solvent and the
coating materials will form a continuous coating film.

Figure 2.8 schematic of organic solvent coating

The organic solvent film coating provides a better and more precise control of the coating
process thanks to the development of the coating apparatus. As a result of this, the
reproducibility of the process and the uniformity of the product from different batch are
efficiently increased. In addition, not only large solid dosage forms such as tablets but
also small solid dosage forms such as pellets can be coated by this technique (Details of
pellets coating with organic solvent coating technique will be introduced in Chapter 2.3.4).
However, several restrictions and drawbacks still exist in this method. Firstly, the
concentration of the coating polymers in the organic solvent is usually dilute, thus it takes
really long processing times to reach an ideal coating thickness and coating level. Also, it
is not available for coating materials with high viscosity as the nozzle is easily blocked.
In addition, the organic solvents may be toxic and inflammable, which brings potential
hazards during the evaporation step. The cost of after-treatment and recovery of the
organic solvent are both very expensive. Moreover, because the organic solvent is
removed through evaporation, the solvent residual may have a chance to remain in the
coating, which indicates a potential safety danger. [1, 22]. Therefore, for some
water-soluble polymers, aqueous film coating begins to take the place of organic solvent
film coating[23].
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2.4.3. Aqueous coating
The aqueous coating method successfully eliminates the usage of organic solvent, which
is a great improvement of this method. The aqueous coating method has a similar coating
procedure as the organic solvent coating method. The aqueous dispersion that contains
the coating materials is sprayed onto the solid dosage forms and curing for a certain
period of time to form a coating film, heat is provided continuously during the curing
step[23]. The film formation mechanism of aqueous coating is different from the organic
solvent coating. The coating materials, instead of dissolving in the aqueous phase,
disperse in water to form a suspension or solution. As shown in Figure 2.9, the film
formation essentially can be divided into three stages. Firstly, the aqueous dispersion
deposits on the surface of the solid dosage forms after being sprayed. Then, as the water
evaporates during the curing step, the polymer particles begin to compact together and
followed by the particle deformation in the second stage. Finally, as the water evaporates
continuously, the particles diffuse and coalesce with each other and form a continuous
coating film.

Figure 2.9 Film formation mechanism of aqueous coating

Whereas, some restrictions still exist in the aqueous film coating method. One of the
major limitations is the huge energy required to evaporate the water during the process
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since water has a higher boiling point than the organic solvent. Another disadvantage is
that the processing time is much longer than the organic solvent coating method due to
the relatively high vaporization latent heat of water. Both of the above-mentioned
drawbacks increase the coating cost and the energy consumption of the process.
Furthermore, some coating polymers may not well-dispersed in water and can cause
nozzle blockage, and thus only organic solvent film coating can be applied to these
materials. Moisture is another key factor that plays an important role in the coating
process. If the API is moisture sensitive, the remaining moisture in the coating film can
cause stability and storage problems[24]. In summary, not only for aqueous coating, but
also organic solvent coating, the balance between the applying solvent (either water or
organic solvent) and its evaporation is the main restriction of these two kinds of coating
methods[25].

2.4.4. Pellet coating with organic solvent/aqueous coating techniques
Coating of small dosage forms such as pellets with the organic solvent coating method or
aqueous coating method is most commonly achieved by the fluidized bed, which
basically includes three types of solution spraying locations, top-spray, side-spray and
bottom spray[26]. The bottom-spray is reached by the Wurster apparatus invented by
Wurster in 1966[27]. Today, it is one of the most common units of coating equipment for
pellet coating in the pharmaceutical coating industry. The schematic of Wurster fluidized
bed is shown in Figure 2.10[28]. The Wurster fluidized bed consists of a
solution-spraying nozzle located at the bottom, a distributor plate and a Wurster tube that
is placed in the center of the column. During processing, the pellets are fluidized and
coated with the coating material sprayed from the bottom spray nozzle. Furthermore, the
unique structure leads the fluidized pellets to circulated between the Wurster tube and the
outside column, which ensures a uniform and continuous coating film. Moreover,
Hampel has came up with a continuous pellets coating by the addition of a separation
tube with the Wurster fluidized bed with organic solvent coating technique[29].
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Drawbacks of this technique are obvious. Large amount of hot fluidizing air is required in
this apparatus not only to maintain the fluidization of the pellets, but also necessary to
keep a constant temperature of the system for moisture evaporation. This increases the
energy consumption as well as the operation cost dramatically. Furthermore, long
processing time is required to achieve an ideal coating level due to the restriction of the
solvent coating method.

Figure 2.10 Schematic of Wurster fluidized bed coating equipment
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Figure 2.11 Schematic of the rotating fluidized bed coater

Apart from the Wurster fluidized bed, another apparatus for coating of small dosage
forms using aqueous coating method is a rotating fluidized bed coater generated by
Satoru Watano[30]. In Satoru’s study, the rotating fluidized bed was aimed at coating
fine particles (Geldart Group C powder) with the HPLC aqueous solution. The schematic
of the rotating fluidized bed is shown in Figure 2.11. The rotating fluidized bed mainly
contains a rotatable cylinder covered with meshes, a plenum chamber and a filter placed
in the center part of the cylinder. During the coating process, the aqueous solution was
sprayed through the nozzle located on the central filter, and the particles were fluidized
with the help of the strong centrifugal force. However, a large amount of hot fluidizing
air is still required in this apparatus in order to maintain the fluidization of the particles
and evaporate the moisture, which dramatically increases the energy consumption. Long
processing time was required due to the nature drawbacks of aqueous coating.
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2.5. Solventless coating processes
As solvent-based coating has some inevitable drawbacks, today, pharmaceutical coating
processes tend to come up with some solvent-free coating techniques, which completely
avoid the use of organic solvent and water. Solventless coating reduces the processing
time and cost of solvent evaporation significantly. Also, the expense of the solvent
follow-up disposal can be decreased dramatically.[25, 31] Typical solventless coating
techniques basically include compression coating, holt-melt coating, supercritical fluid
coating, photocurable coating and dry powder coating. Particularly, dry powder coating is
a novel solventless coating technique that has drawn great attention in the pharmaceutical
coating industry. Dry powder coating includes several coating techniques such as
electrostatic-infrared powder coating, infrared-heat powder coating, plasticizer powder
coating, etc. Detailed introduction of dry powder coating will be introduced in Chapter
2.5.

2.5.1. Compression coating
Compression coating, also named press coating, is mainly applied for the coating of
tablets. It is comprised of a drug core and an outer shell. The drug core is enclosed in the
outer shell and thus different drug release patterns can be modulated by the selection of
inner drug cores and outer layer materials. Also, the outer shell has great influence on the
mechanical strength and stability of the coated tablets[32].
Conventionally, the compression coating process is accomplished by firstly compressing
the drug core, and followed by compressing the outer layer materials around the drug
core. A major problem related with the technique is the location of the inner drug core.
The drug delivery performance of the coated tablet is not desirable assuming that the
location of the drug core is not in the center[33]. This problem was solved by Ozeki et al.
who designed a one-step-dry-coated tablet manufacturing method (OSDRC system). This
method has been successfully applied to modify delayed release, and the API release time
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and release profile can be controlled by adjusting the thickness of the outer layer [32, 34,
35]. Hariharan and Gupta reported a similar process, in which a modified three-layer
tablet press was used and the drug core and coated tablets are made simultaneously[36].
Tahra et al. found that HPMC was suitable for sustained release using compression
coating method[37]. Cellulose derivatives, for example, hydroxypropylmethylcellulose
(HPMC), hydroxyethlcellulose (HEC) and hydroxypropylcellulose (HPC) are appropriate
polymers for the outer layer materials to modify controlled release and sustained release
in compression coating[32].
Compression coating has some unique features. Firstly, it is able to modulate controlled
release and sustained release, and particularly, it allows the drug core to be coated with
some incompatible coating polymers. Moreover, it also available for the coating of those
tablets that contain two kinds of APIs with different target area[25]. However, the
compression coating has some drawbacks as well. One of the major limitations is the
large coating thickness. The drug loading is limited due to the thick outer layer. It also
restricted by the compressibility of the coating materials. Moreover, for the small dosage
forms, such as pellets, that have quite small drug loading and volume, the compression
coating technique is not suitable and efficient when applying to this kind of substrates.
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2.5.2. Hot-melt coating
In hot-melt coating process, as its name indicates, the coating material is applied in the
molten state on the substrate and followed by a cooling solidification step, in which no
solvent is required. This technique has been researched for stability improvement, taste
masking and sustained release[31]. The release performance of the coated drug is
determined by the coating material and is influenced by several factors such as pH, heat
contact with digestive enzymes during diffusion, penetration behaviors, etc.[38].

Figure 2.12 Schematic of the hot-melt coating process[40]

In general, the process of hot-melt coating can be divided into four stages: warming up of
equipment, preheating of substrate, melting and spreading of the coating material and
finally cooling and congealing of the coating[39]. A schematic of the hot-melt coating
process is shown in Figure 2.12. The equipment is a modification of conventional
fluidized bed coater, and consists of a coating material molten system, an insulated
nozzle for the spraying of coating agent and a modified fluidized bed[40]. When
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processing, the coating agent is introduced at a high temperature (around 150 oC)
constantly. As a result, the hot-melt coating materials must be equipped with low melting
points, stable physical and chemical properties, good flowability and sprayability[38].
Commonly used coating materials in hot-melt coating technique are usually derived from
natural animal and plant sources, such as partially hydrogenated soybean oil, partially
hydrogenated palm oil, partially hydrogenated cottonseed oil and partially hydrogenated
castor oil, paraffin wax, to name a few[31, 38-40].
In summary, hot melt coating is useful for coating of small dosage forms such as small
granules, pellets and particles. Moreover, coating polymers with low melting point is
suitable to be applied in this method and the process can be accomplished within a short
time. However, many APIs of the drug cores cannot sustain under high temperatures
because they are very easy to decompose or damage. In addition, the selection of coating
materials is very limited. Many commonly used pharmaceutical coating materials usually
have high melting point, and dilution is required if applying with the hot-melt coating
technique. Therefore, the hot melt coating still has some restrictions to achieve high
quality coatings.

2.5.3. Photocurable coating
The photocurable coating method is mainly based on a free-radical polymerization
reaction. Wherein, the functional groups in the photocurable materials react due to the
illumination of an UV/visible light source and achieve a crosslinking reaction. The
process can be finished within a short time[41]. The photocurable coating system
contains three key components: an UV/visible light source, functionalized liquid
monomers/prepolymers as the photocurable materials and photoinitiator or/and photo
sensitizer[42]. Depending on the monomers/prepolymer and the photoinitiator applied,
the polymerization reaction generated by the light could be free radical, cationic or
anionic mechanisms[43]. During the polymerization reaction, the functionalized liquid
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monomers/prepolymers transform from the liquid state to the coating film. The most
widely applied photocurable coating materials is acrylate-functional pre-polymers[44].
Wang and Bogner were the first who applied the solventless photocurable coating
technique to pharmaceutical area. They coated nonpareil beads with silicone polymer
derivatives[45]. Later on, Bose and Bogner extended the technique to modifying
immediate and sustained drug release profiles[46]. The release profiles are modulated by
the adjustment of the coating materials, the layer numbers and the coating thickness. The
film

formation

of

the

coating

relies

on

the

concentration

of

the

photo-initiator/photosensitizer, the intensity of the light source and the illumination time
of the light[47].
In summary, the photocruable coating method is a chemical reaction-based technique and
is suitable for APIs that are sensitive to high temperature. Both tablet coating and pellet
coating can be achieved with this technique. Moreover, the processing time is quite short
compared to liquid-based coating techniques. On the contrary, for light sensitive drugs,
this coating method is not a good choice. The UV photocurable polymers are still not
generally recognized as safe (GRAS listed)[25]. Therefore, the application of this
technique to the pharmaceutical field still needs further exploration.

2.5.4. Supercritical fluid coating
Supercritical fluid coating is another novel solventless coating technique. The definition
of supercritical state is a state that the temperature and pressure of a substance are above
its critical temperature and critical pressure. Under this state, the phase state between
liquid and gas is not obvious, which indicates that it can act like gas or behave like liquid.
In addition, at the point close to critical state, a small change in pressure or temperature
may result in great variation in physical and chemical properties[48].
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The process can be accomplished by the following steps: firstly, to dissolve the coating
agent in the supercritical fluid (supercritical carbon dioxide), then to disperse the coating
materials in the medium, finally to achieve the coating by a rapid expansion of the
supercritical solutions[49]. One of the common processes of supercritical fluid coating in
pharmaceutical field is rapid expansion of supercritical solutions (RESS), as shown in
Figure 2.13[49-51]. The most commonly used supercritical solution is supercritical
carbon dioxide. Since it has relatively low critical temperature (31.1 oC) and critical
pressure (72bar), its supercritical state is able to be achieved near room temperature. In
supercritical state, carbon dioxide has liquid-like density and dissolubility, and gas-like
diffusivity. Therefore, carbon dioxide is a suitable choice for supercritical state[52].

Figure 2.13 Schematic of rapid expansion of supercritical solutions (RESS) process

All in all, the supercritical fluid coating is beneficial to small dosage forms coating, such
as pellets and glass beads[50, 51, 53, 54]. In addition, the coating process can be
completed within a short time owing to the quickl elimination of the supercritical fluid.
Whereas, this technique still has some restrictions. Firstly, most coating materials have a
relatively low solubility in the supercritical fluid, which limit the properties of the coating
materials. Secondly, the drug core should remain insoluble during the whole coating
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process. Finally, the cost of the equipment is relatively high. Since the supercritical fluid
in this process is in a high-pressure state, some special equipment that meets this demand
needs to be investigated when applied in pharmaceutical industry[25].

2.6. Dry powder coating
Dry powder coating belongs to solventless coating, and can be divided into several
coating techniques, including electrostatic-infrared powder coating, infrared-heat powder
coating, plasticizer powder coating and electrostatic-heat-plasticizer (PEH) powder
coating. This novel coating technique has began to draw great attention from the
pharmaceutical industry owing to its unique characteristics such as short processing time,
high coating efficiency, and low energy consumption, to name a few.

2.6.1. Electrostatic-Infrared powder coating
Electrostatic-Infrared powder coating was first applied in automobile and paint coating
industries and then ‘transplanted’ to pharmaceutical coating industry in the last several
decades. In this technique, the coating materials, carried by air, are charged by a high
voltage (up to 100kV/200µA) electrostatic spray gun, and disperse to the surface of the
grounded substrates. After the electrostatic adhesion, the powders are melted to form a
strong coating film under the exposure of IR radiation that serves as a heat source[55].
The efficiency of the powder adhesion on the grounded solid dosage forms is relatively
high. This is because the electrons of the charged coating particles will release to the
ground when in contact with the grounded solid dosage forms immediately, which won’t
have any resistance on the deposition of the next feed coating particles.
The coating materials and the solid dosage forms are required to be conductive.
Particularly, the drug core must have a resistivity under 109Ωm for the purpose of
grounding while in contact with those charged coating powders. Various methods have
been applied to increase the conductivity of the drug core. One efficient way is to spray
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some water on the drug core to bring moisture onto the surface, which can help to
decrease the resistivity. Another method is modifying the substrate with the help of
excipients such as quaternary ammonium compounds and ionic salts. These excipients
increase the conductivity through the absorption of the moisture in the air, and can
generate a gel layer that is electrically conductive[55].
The coating materials usually have a size that ranges from 30 to 100µm, and sometimes
contains more than one component. This can avoid agglomeration so that the particles act
the same. A similar particle size of the coating materials means a better deposition on the
surface of the solid dosage forms and the distribution behaves more uniformly[56].
Compared to solvent-based coating, the film thickness of electrostatic powder coating is
thicker, sometimes maybe twice that over solvent-based coating. Moreover, the resistivity
of the coating materials has a great influence on the control of the film thickness. Usually,
low resistivity (108Ωm) indicates a poor deposition due to the loss of charge. In contrast,
high resistivity (1012Ωm) may lead to back ionization, which also limits the powder
deposition and coating thickness[57]. After the spraying process, the coating powder
forms a uniform film through exposure under IR radiation. The temperature of the drug
core is around 80 oC, and 120oC of the coating materials[56].
Phoqus, an oral drug delivery and development pharmaceutical company, has
commercialized electrostatic-infrared powder coating technique[58-61]. In their process,
the deposition of the coating powder is under accurate control and the two sides of the
solid dosage forms can be coated with different formulations.
In conclusion, the electrostatic-infrared powder coating is a novel technique in the
pharmaceutical industry. A uniform coating film can be achieved through this method
within a short processing time. Furthermore, for water-sensitive drugs, this technique is a
suitable choice. Moreover, this method has been applied to both the coating of large
dosage forms and small dosage forms such as fine particles (details will be given in
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Chapter 2.5.5)[62]. However, some limitations still exist in this technique. Infrared heat
is necessary during the film formation process, which means this is not applicable for
heat-sensitive drugs. In addition, despite the processing time being short, the time
required for cleaning of the apparatus is relative long, which makes the process more
complicated.

2.6.2. Plasticizer powder coating
Plasticizer powder coating was first reported by Obara et al[16]. The basic principle of
this technique is to feed coating materials and liquid plasticizers simultaneously from two
different feeders, and followed by a curing step to achieve a continuous coating film
(shown in Figure 2.14[54]). Particularly, the curing temperature must be greater than the
glass transition temperature (Tg) of the coating materials.

Figure 2.14 Schematic of plasticizer powder coating

During the coating process, the plasticizers increase the free volume by incorporating
themselves between the polymers chains and thus result in the decrease of Tg, sometimes
dramatically[12-14]. As the coating temperature can be decreased with the help of the
plasticizer, the API is protected efficiently from being damaged[54, 63, 64]. Plasticizers,
after being sprayed onto the surface of the solid dosage forms, can contribute to the
adhesion between the coating particles and the solid dosage forms. It is beneficial for the
film formation due to the improvement of viscous flow and particle deformation[65].
Furthermore, capillary forces will generate before the plasticizer immerse into the solid
dosage forms, therefore, the deformation in the interstitial capillary system and the film
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formation can be improved as well[16, 65].
Common used liquid plasticizers are triethyl citrate (TEC), polyethylene glycol 400
(PEG400), acetylated monoglyceride (AMG), etc. Particularly, for a certain coating
polymer, a limited choice of the plasticizers can decrease its Tg efficiently.
So far, many research groups have applied the plasticizer powder coating technique to
modulate fast release, sustained release and controlled release[16, 63-67]. The coating
substrates can be either large solid dosage forms like tablets or small ones like pellets and
particles. Usually, coating of tablets is processed in a rotating pan coater, and coating of
pellets and particles are in a Wurster fluidized bed because small solid dosage forms tend
to agglomerate easily due to the strong interactions and large specific surface areas.
(Details of small dosage forms coating with the plasticizer powder coating technique will
be introduced in Chapter 2.5.5.)
The major advantage of the plasticizer powder coating technique is the short processing
time compared with solvent-based coating methods. In contrast, this technique still face
challenges in some aspects. One is that the amount of plasticizers applied in the process is
difficult to control. Surplus plasticizers may cause sticky effect and agglomeration of the
solid dosage forms, whereas, not enough amount may result in a thin coating film and un
uniform coating material deposition[54]. Thus, balance between the amount of plasticizer
and prevention from agglomeration plays a critical role in the plasticizer powder coating
technique.

2.6.3. Infrared-Heat powder coating
Infrared-Heat powder coating was first studied by Cerea et al. and was designed for the
coating of tablets. In this technique, heat is the binding force that helps the formation of
the coating film and is provided by an infrared (IR) light source[68]. Plasticizers are not
required in this method. For polymers with low Tg such as Eudragit® EPO (Tg=53 oC), the
29

coating process is simple: spreading the coating material on to the tablets and curing
under the illumination of the IR light source. When referred to high Tg polymers like
Eudragit® RL (Tg=62 oC), Eudragit® RS (Tg=59 oC) and Eudragit® L 100-55 (Tg=127 oC),
a pre-plasticization step is required, in which the coating polymer is combined with
plasticizers through a hot melt extrusion process[17].
Advantages of the infrared-heat powder coating method included the elimination of
plasticizers for those low Tg polymers, and the reduction of the plasticizer amount of high
Tg polymers thanks to the pre-plasticization. However, the coating film accomplished by
this technique is not smooth and uniform, and the thickness is large although the
functional drug delivery is reached successfully. Furthermore, since the application of
heat powder coating on tablets was successful, the coating of small solid dosage forms
such as pellets with this method still requires further study.

2.6.4. Plasticizer-electrostatic-heat powder coating
Plasticizer-electrostatic-heat powder coating technique (PEH-Coating) is a novel
pharmaceutical coating technique developed by Zhu et al[69]. As the name referred, this
technique combines the application of plasticizer, electrostatic deposition and the heat
together in one coating system. The liquid plasticizers help to decrease the glass
transition temperature (Tg) of the coating materials, generate a capillary force and
increase the electrical conductivity of the solid dosage forms. Moreover, the electrostatic
spraying gun charges the coating particles with negative electrons and work together with
the grounded rotating coating pan, which improves the powder adhesion on the solid
dosage forms effectively. After the charged particles attach on the solid dosage forms, the
electrons will release to ground due to the electrical conductivity of the solid dosage
forms and the grounded pan coater, thus the next layer of the charged coating particles
can easily deposit on the surface of the solid dosage forms again.
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The PEH-Coating technique is achieved in a rotating pan coater. As shown in Figure 2.15,
four major parts are included in this coating apparatus, a liquid plasticizer spraying
system, a coating material feeder, an electrostatic spraying gun that can generate
electrons together with coating materials and a grounded rotating coating pan that is
temperature controllable. The overall coating process includes the following steps: firstly,
the solid dosage forms are preheated in the rotating pan coater at a pre-determined
temperature; secondly, a given amount of plasticizer is sprayed onto the solid dosage
forms and immediately followed by the electrostatic spraying of the coating materials at a
given amount; finally, the pellets are cured at a pre-determined temperature and time to
form a continuous, smooth and strong coating film.

Figure 2.15 Schematic of PEH-Coating system. (A) Liquid plasticizer spraying system,
(B) Rotatable coating pan, (C) Electrostatic spraying gun, (D) Coating material feeder

This technique has been applied to the coating of both large solid dosage forms such as
tablets and small solid dosage forms such as pellets and successfully modified immediate
release, sustained release and delayed release with relevant coating materials[10-12, 70].
Advantages of the PEH-Coating technique are clearly illustrated. It avoids the usage of
the organic solvent and the water, which avoids the potential hazards of the organic
solvent and shortens the processing time effectively. The coating process can be
shortened to 2-3 hours. Also, since no fluidizing air is required in this technique, the
energy
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compared

to
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pharmaceutical coating fluidized bed coater that need large amount of hot fluidizing air to
evaporate the liquid. In contrast, the restrictions of this technique still exist. The coating
of those solid dosage forms with less electrical conductivity is not appropriate in this
coating system. Moreover, the rotating pan coater in this technique is an ‘open system’,
as a result, this is not a good selection for the coating of solid dosage forms with a really
small size and weight. This is because during the coating process, the rotating pan coater
may lead to the drop of tiny pellets, and the air from the spraying gun will blow the small
pellets away.

2.6.5. Pellets coating with dry powder coating techniques
As described above, many of the dry powder coating techniques are able to achieve the
coating of small solid dosage forms such as pellets and fine particles. The commonly
used apparatus in dry powder coating techniques are spout-fluidized bed (Figure 2.16,
applied in electrostatic-infrared powder coating), Wurster fluidized bed (Figure 2.10,
applied in plasticizer powder coating) and rotating pan coater (Figure 2.15, applied in
PEH powder coating).

Figure 2.16 Schematic of the electrostatic spout-fluidized bed system[62]
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The electrostatic-infrared coating technique has also been applied to the coating of small
dosage forms such as fine particles with a spout-fluidized bed apparatus[62]. The
schematic of the electrostatic spout-fluidized bed system is shown in Figure 2.16. The
process was operated under a diluted and fast circulating condition in the spout-fluidized
bed. Specifically, the particles were fluidized by the warm fluidizing air and were
plasticized by the plasticizer nozzle located at the bottom of the column, meanwhile, the
coating powders were charged with electrons by a corona gun and attached to the
plasticized particles. Then the coated particles were transported from the spout-fluidized
bed to a stationary system and followed with a curing step under the IR lamp at a
predetermined temperature. Delayed release was successfully modified by the
hydroxypropyl methylcellulose acetate succinate (HPMCAS) in this system. The
advantages of this system with electrostatic-infrared dry powder coating technique are:
firstly, it can avoid the agglomeration of the fine particles in the coating process
effectively; secondly, it is suitable for the coating of fine particles even with a particle
size less than 1mm. However, drawbacks of this technique still exist. Due to the
characteristic of the fluidized bed, large amount of hot fluidizing air is required in this
system, which increases the energy consumption as well as the operation cost. In addition,
although the coating step in the spout-fluidized bed can be operated quickly, the curing
step takes up to12 hours to achieve an ideal coating film.
Coating of small dosage forms using the plasticizer powder coating technique was
available in a Wurster fluidized bed (Figure 2.10), which was investigated by Bodmeier
research group[63, 64, 71]. In their study, the nonpareil pellets with a size of 0.71-0.85
mm were employed and coated with different coating materials to modify immediate
release, sustained release and delayed release. During the coating process, the spraying of
plasticizer and the feeding of coating materials were induced separately in a Wurster
fluidized bed, and after the adhesion of the coating materials, the pellets were unloaded
and transported to a curing step for another 2 h to 24 h under the predetermined
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temperature. Obviously, pellet coating in a Wurster fluidized bed with the plasticizer
powder coating technique decreases the adhesion between the coated pellets efficiently.
The processing time can be shorten within several hours depended on the required curing
time of the coating materials. A large amount of hot fluidizing air is required in this
system due to the limitation of a Wurster fluidized bed, which increases the energy
consumption and operating cost.
The coating of small pellets with the PEH powder coating technique was achieved in a
rotating coating pan (Figure 2.15). The coated pellets were able to modulate immediate
release, sustained release and delayed release with relevant coating materials
successfully[12]. Details of this coating system can be found in Chapter 2.5.4.
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3.

Chapter 3
Materials and Methods

3.1. Materials
3.1.1. Powders
Eudragit® EPO, Eudragit® RS, Eudragit® RL, Eudragit® L100-55 and Colloidal silicon
dioxide (AEROSIL® 200 Pharma) were provided by Evonik Degussa Corporation
(Germany). Eudragit® EPO was used as the fast release coating polymer, and Eudragit®
RS, Eudragit® RL were used as the sustained release coating polymers. Acryl-EZE was
donated by Colorcon, Inc. (US). Acryl-EZE was used as the delayed release coating
polymer and contains Eudragit® L100-55 developed by Colorcon, Inc. Talc powder was
purchased from Mallinckrodt Baker Inc. (Canada). Colloidal silicon dioxide and talc
powders were served as the anti-adherent agent to facilitate the coating process.

3.1.2. Plasticizers
Polyethylene glycol 400 (PEG 400) was purchased from EMD Chemicals Inc. (Ontario
Canada). Triethyl citrate (TEC) was purchased from Caledon Laboratories Ltd. (Ontario
Canada). The selections of liquid plasticizers were based on their performance of
reducing the glass transition temperature (Tg) of the coating polymers. PEG 400 was
selected as the liquid plasticizer for both Eudragit® EPO and Acryl-EZE. TEC was
chosen as the liquid plasticizer for Eudragit® RS and Eudragit® RL[12].

3.1.3. Piroxicam pellets
Piroxicam pellets and microcrystalline cellulose (MCC) pellets were provided by
Gaocheng Biotech Health CO., Ltd. (China). The particle size of the piroxicam pellets
and MCC pellets are 0.9 -1.10 mm and 0.1-0.3 mm, respectively.
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3.2. Particle size reduction and analysis
Particle size reduction is necessary for the coating powders (Eudragit® RS and Eudragit®
RL) in order to achieve uniform film coating before preparing the coating formulations.
A blade grind mill was employed as the particle size reduction apparatus, and an
ultrasonic sieving (HK Technologies Ultrasonics Rugby, United Kingdom) was applied
to select the powders with ideal particle size.
The particle size of powders was validated by a particle size analyzer (TSI Corporation,
Model 3603, Shoreview, MN, USA) after the particle size reduction. The volume mean
diameter D[4,3] was used as the average particle size. The calculation equation is as
follows:
n

D [ 4,3] =

4
i i

∑D V
1
n

3
i i

∑D V
1

The particle size tests were replicated three times. The average particle size of coating
powders was shown in Table 3.1.

Table 3.1 Particle size of coating powders and additives
Coating powder

Average particle size, D[4,3] (µm)

®

Eudragit EPO

13.3

®

47.7

Eudragit RL

®

40.8

Acryl-EZE

20.5

Talc

28.9

Eudragit RS
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3.3. Glass transition temperature
Differential scanning calorimetry (DSC) analysis (Mettler Toledo, DSC822, Mississauga,
Canada) was employed to study the glass transition temperature of both raw coating
materials and coating materials with liquid plasticizers. The tests were investigated under
different weight ratios between the plasticizers and coating materials. The samples (10
mg) were heated at the rate of 2 oC /min under a nitrogen atmosphere with the range from
20 oC to 200 oC. For each sample, the test was replicated twice[11]. The DSC results are
shown in Table 3.2, Table 3.3 and Table 3.4.

Table 3.2 Glass transition temperature of Eudragit® EPO
o

Plasticizer (PEG 400) ratio

®

Tg ( C) of Eudragit EPO

(%w/w, based on polymer)
0

53.1

10

38.8

25

31.1

Table 3.3 Glass transition temperature of Eudragit® RS and Eudragit® RL
Plasticizer (TEC) ratio

o

®

o

®

Tg ( C) of Eudragit RS

Tg ( C) of Eudragit RL

0

62

59

15

45

46.5

30

36

38

45

25

26

(%w/w, based on polymer)
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Table 3.4 Glass transition temperature of Acryl-EZE
o

Plasticizer (PEG 400) ratio

Tg ( C) of Acryl-EZE

(%w/w, based on polymer)
0

127

10

102

25

87

50

75

100
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3.4. Characterization using scanning electron micrographs
(SEM)
The surface morphology of the coated pellets was investigated by the scanning electron
microscopy (SEM). An EMITECH K550 sputter coater (Emitech Ltd., Ashford, UK) was
employed to sputter coat the pellets samples. After sputter coated, the pellets samples
were observed under a scanning electron microscope at 5.0 kV (SEM, Hitachi S-2600N,
Ontario, Canada).

3.5. In-vitro drug release testing
In-vitro drug release profiles of the coated pellets were tested by the United States
Pharmacopeia (USP) apparatus (Apparatus 2, paddle; Huanghai Rcz-6c2, Shanghai,
China). Six samples with 100mg coated pellets were conducted for the three different
polymers coated pellets. For Eudragit® EPO coated pellets, the drug release media was
900 mL of 0.1 N HCl solution under the temperature of 37 oC and the rotation speed of
the paddle was 100 rpm. For Eudragit® RS and Eudragit® RL coated pellets, the drug
release media was also 900 mL of pH 7.2 phosphate buffer solution under the
temperature of 37 oC and the rotation speed of the paddle was 50 rpm. For Acryl-EZE
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coated pellets, the release media was 750 mL of 0.1 N HCl solution during the first 2h
and 1000 mL of pH 6.8 phosphate buffer solution (by the addition of 250 mL of 0.2 M
tribasic sodium phosphate solution into the above 750 mL 0.1 N HCl solution) for
another 2h, and the rotation speed of the paddle was 100 rpm. Samples were collected by
a 10 mL syringe at predetermined intervals and followed by the replacement of same
amount (10 mL) of fresh release media. The samples, after being filtered, were assayed
using an 8453 UV-Visible Spectrophotometer (Agilent Technologies, Mississauga,
Canada) at a wavelength of 334 nm for pH 1.2 HCl solution (0.1 N), 354 nm for pH 7.2
phosphate buffer solution and 353 nm for pH 6.8 phosphate buffer solution.
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3.5.1. Standard curve
The drug release standard curves of piroxicam at the wavelength of 334 nm, 354 nm and
353 nm are shown in Figure 3.1, Figure 3.2 and Figure 3.3, respectively. The curves are
served for the calculation of unknown concentrations of piroxicam samples collected
from the in-vitro drug release testing.

Figure 3.1 Standard curve of piroxicam (wavelength=334 nm)
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Figure 3.2 Standard curve of piroxicam (wavelength=354 nm)
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Figure 3.3 Standard curve of piroxicam (wavelength=353 nm)
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3.5.2. UV-Vis spectrophotometer validation
After the creation of the standard curve of piroxicam, precision test, accuracy (recovery)
test and stability test are required for the acceptability validation of the application of
UV-vis spectrophotometer that is used for the measurement and analysis of the drug
release from piroxicam pellets. For the release media of pH 1.2 HCl solution (0.1 N), a
buffer solution containing piroxicam was scanned by the UV-vis spectrophotometer to
ensure a maximum absorbency wavelength at 334 nm. For the release media of pH 7.2
phosphate buffer solution, the wavelength is at 354 nm. And for the release media of pH
6.8 phosphate buffer solution, the wavelength is at 353 nm. After the confirmation of the
maximum absorbency wavelength of different release media with known concentration,
the three-mentioned test (precision test, accuracy (recovery) test, stability test) were
required for each of the release medium.
Precision tests
Three solution samples with a known concentration of piroxicam (not to exceed the
maximum absorbency concentration of the standard curve) were prepared, and then
scanned a defined amount of each sample. The standard of the precision test depends on
the standard error between the three samples that are collected from the UV-vis
spectrophotometer output. If the standard error is smaller than 1%, the precision test is
successful. The equation for the calculation of standard error is:

Standard Error =

Standard deviation of sample
< 1%
Mean drug release concentration
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Accuracy (recovery) tests
Three solution samples of different known piroxicam concentration were prepared. The
concentrations of three samples are low, medium and high. Then scanned a defined
amount of each sample was scanned. The definition of the accuracy test is the difference
between the true value and the mean experimental value of the release data within a
confidence interval. The accuracy test is required for each of the three concentration
samples. The three tests will give an overall accuracy of the UV-vis spectrophotometer.
The calculation equation of percentage difference is:

Percentage Difference =

(True value-Mean experimental value)
* 100%
True value

Stability tests
For stability test, a solution sample of known piroxicam concentration (not exceed the
maximum absorbency concentration of the standard curve) was prepared. Then the
solution sample was put into one chamber of the dissolution test apparatus and the
temperature of the system was 37 oC. Samples were collected with a 10 mL syringe at
predetermined intervals (0 hr, 1 hr, 2 hrs, 6 hrs, 12 hrs) and scanned. Sample of 0 hr was
regarded as the basis. If the experimental value of the samples through 12 hours,
compared to the 0 hr basis, remained constant within a very tiny error, the accuracy test
can be regarded as a success.
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4.

Chapter 4
Apparatus and Experimental Procedure

4.1. An innovative rotary fluidized bed equipment for pellets
dry powder coating
Rotary fluidized bed (RFB) coating system
A new apparatus called Rotary Fluidized Bed (RFB) was designed by our research group
for the coating of small dosage forms with dry powder coating technique. The apparatus
structure originated from the fluidized bed that facilitated fine powder fluidizing[72]
Figure 4.1 shows the schematic of this rotary fluidized bed that is seen horizontally along
with the rotating axis. Wherein, the rotating part of the RFB is a cylindrical tank
(diameter =12 cm, depth= 10 cm) lying horizontally. The cover of the cylindrical tank
can be removed for the loading of the solid dosage forms. There is an open hole (2 cm)
located in the center of the cover that serves as the inlets of the coating materials and
plasticizers. Particularly, the cylindrical tank consists of two layers. The outside layer is
made of acrylic and the inner side is covered with porous material (mesh). There are six
chambers located between the two layers. During processing, a fluidizing air is blown in
through three of the six chambers and the other three chambers serves as outlets. When
rotating, the six chambers serve as inlets and outlets alternately. The rotation speed of the
tank can be controlled. In addition, fluidizing air is introduced in to the rotating tank
during the coating process. The air enters through the backside of the rotating tank, then
circulates in the tank and flows out again from its backside. The temperature of the
coating system is controlled by the fluidizing air. Figure 4.2 shows the schematic of the
RFB coating system that is comprised of four major parts, the coating materials feeder,
the liquid plasticizer spraying system, the RFB and the fluidizing air heating and
introducing system.
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Figure 4.1 Schematic of rotary fluidized bed

The rotary fluidized bed (RFB) is an innovative apparatus for dry powder coating of
small solid dosage forms such as pellets and particles. Advantages of the RFB are as
follows. Firstly, compared to conventional solvent-based coating methods, the processing
temperature is greatly decreased. Taking the Acryl-EZE coated pellets as an example, the
processing temperature (curing temperature) using dry powder coating with RFB is 50 oC
while it is always higher than 50 oC of conventional solvent-based coating. Secondly,
processing time can be decreased to only 2-3 hours. For conventional solvent-based
coating it usually takes up to 10-20 hours to reach the same coating level. The flow rate
of fluidizing air in the RFB is less than that of liquid-based coating in fluidized bed coater.
In addition, the inner side of the rotating tank is covered with porous material (mesh),
which can release the moisture efficiently. Furthermore, the combination of rotation and
fluidizing air successfully avoids agglomerations of pellets. Also, the fluidizing air is able
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to blow the unattached coating powder away from the surface of the pellets, which can
improve the smoothness of the pellet coated surface.

Figure 4.2 Schematic of the RFB system:(A) Coating materials feeder,
(B) Liquid plasticizer spraying system, (C) Rotary fluidized bed,
(D) Fluidizing air heating and introducing system

Experimental procedure and operating conditions
The experimental procedure of coating pellets using dry powder coating technique with
RFB comprises five main steps: coating material formulation preparation, pellets and
equipment preheating, liquid plasticizer spray, coating materials feeding and finally
curing step.
The first step, preparation of coating material formulation, was to combine the coating
polymers (Eudragit® EPO, Eudragit® RS, Eudragit® RL and Acryl-EZE) with additives
(talc, colloidal silicon dioxide and pigment) into a homogeneous formulation. The ratio
between the coating polymers and additives depended on the weight.
The second step was preheating of the equipment and pellets. In this step, 40g piroxicam
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pellets were loaded into the rotating cylindrical tank and fluidizing air was introduced
with a given temperature to warm up the equipment and pellets. The rotating speed of the
RFB was based on the given process conditions.
Once the temperature of the pellets achieved the given temperature, the liquid plasticizer
was sprayed and immediately followed by the feeding of coating materials. Before
spraying liquid plasticizers, the rotation of the RFB was set to a relatively high speed that
was about 70 rpm. This is because when spraying liquid plasticizers, pellets tend to
agglomerate and become sticky, thus an increase in the rotating speed can avoid the
agglomeration effectively. The fluidizing air was stopped before the spraying step in
order to avoid the blow-away of coating materials. Liquid plasticizer was sprayed onto
the pellets at a given flowrate from an atomizing nozzle. The spraying time was about 30
to 40 seconds based on the different coating polymers. It was followed immediately by a
coating material feeding step. Whereby, a given amount of coating materials (usually
1-1.5 g) was delivered into the cylindrical tank. Usually, the plasticizer spray step and
coating materials feed step was repeated several times until enough coating materials
were deposited on the pellets and an ideal coating level was achieved. A waiting period
(usually 10-20 mins) was required before the next amount of plasticizer and coating
materials were feed. During the wait time, the fluidized air was re-introduced at the same
processing temperature.
The final step of the coating process is the curing of coating materials that helps to form a
uniform and stable coating film. The curing step began after the final spraying of liquid
plasticizers and feeding of coating materials. In this step, the rotating speed and the
curing time depended on the process parameters.
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The coating level (%) of the coated pellets was defined as the weight gain of coated
pellets over the weight of uncoated pellets, as shown in the following equation:

Coating level (%) =

weight of coated pellets - weight of uncoated pellets
* 100%
weight of uncoated pellets

4.2. Rotating pan coater
Rotating pan coater system
A rotating pan coater system, which was designed by our research group, was introduced
for the coating of pellets with dry powder coating method. A schematic of the rotating
pan coater system was shown in Figure 4.3. It consists of four main parts, a liquid
plasticizer spraying system that includes an atomizing nozzle and a metering pump, a
coating materials feeder, a rotating coating pan (with a diameter of 12.8 cm and a depth
of 12.8 cm) and a coating materials spraying gun. The rotating speed of the coating pan
and its processing temperature is controllable.

Figure 4.3 Schematic of the rotating pan coater system:
(A) Liquid plasticizer spraying system, (B) Coating pan,
(C) Coating material spraying gun, (D) Coating materials feeder
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Experimental procedure
The experimental procedure using the rotating pan coater is similar to the RFB, which
also contains five main steps, including coating material formulation preparation, pellets
and equipment preheating, liquid plasticizer spray, coating materials feeding and finally
curing step.
The first step, preparation of coating material formulation, was the same as it was in the
RFB procedure. Then, the piroxicam pellets (70g) was placed in the rotating pan coater
and preheated to a predetermined temperature that depended on the coating polymers.
When preheating, the rotating speed was relatively slow.
Next was to spray the liquid plasticizer and feed the coating materials. Prior to the above
two steps, the rotating speed was adjusted to a relatively high rate for the purpose of
avoiding the pellets from agglomeration when applying the liquid plasticizer. Then, a
given amount of liquid plasticizer was sprayed onto the pellets from an atomizing nozzle,
followed by feeding of a given amount of coating materials right away. This step was
usually repeated several times until enough coating materials were deposited on the
pellets and an ideal coating level was achieved. Particularly, a waiting period (usually
10-20 mins) was required before the next amount of plasticizer and coating materials
were feed.
When enough coating materials were attached onto the pellets, the curing step started.
The rotating speed was readjusted to a slow rate (10-20 rpm) in order to reach a stable
and uniform coating film. This step usually took about 2 hours and the processing
temperature was maintained constantly at a given value.
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4.3. Traditional fluidized bed
Top-spray fluidized bed system

Figure 4.4 Schematic of top-spray fluidized bed

A traditional fluidized bed (column diameter=5 cm, expansion chamber diameter= 7.8cm,
column height=20 cm, overall height=36 cm,) was used for dry powder coating small
solid dosage forms. Schematic of the top-spray fluidized bed was shown in Figure 4.4.
The pellets and coating materials were loaded in the fluidized bed above the distributor
prior to a fluidization introduce. There was an atomizing nozzle placed in the middle of
the fluidized bed that served for liquid plasticizer spraying. Fluidized air was induced
from the bottom of the bed and the temperature of the system was also controlled by the
introduced fluidizing air.
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Experimental procedure
The experimental procedure of using top-spray fluidized bed was comprised of
preparation of coating material formulation, pellets and equipment preheating, loading of
coating materials, liquid plasticizer spray and curing step.
The preparation of the coating material formulation step followed the same procedure as
the above two. Then the pellets with a weight of 70 g were loaded in the fluidized bed,
and fluidizing air was introduced with a given flowrate and temperature to fluidize and
preheat the pellets. When reaching the predetermined temperature, the fluidizing air was
shut down and a given amount of coating materials was placed onto the distributor (The
pellets were reloaded after the coating materials were settled). The next step was the
liquid plasticizer spray, wherein the fluidizing air was introduced at a given flowrate,
meanwhile a given amount of liquid plasticizer was sprayed from the atomizing nozzle
located in the middle height of the column. At this moment, the liquid plasticizer, coating
materials and the pellets contacted with each other together and the pellets were attached
with coating materials immediately. The final step was the curing of the pellets, in which
the fluidizing air was maintained at a constant flowrate and temperature until a uniform
coating film was achieved.

52

5.

Chapter 5
Dry Powder Coating of Pharmaceutical Pellets
with the Rotary Fluidized Bed

5.1. Immediate release coating with Eudragit® EPO
5.1.1. Introduction
Immediate release is aiming at a rapid dissolution of drug after oral administration, which
can quickly get the drug into the blood stream and take action to the site immediately.
Among the commonly used immediate release coating materials, Eudragit® EPO has a
good performance on taste masking which is one of the reasons of immediate release
coating. Furthermore, it has already been mentioned that Eudragit® EPO is able to
dissolve in gastric solutions up to pH5.5. This implies it is insoluble in the saliva but will
dissolve in stomach rapidly[3].
Previous work done by our research group has shown that the pellets coating with
Eudragit® EPO by dry powder coating technique was successfully achieved by a rotating
pan coater[12]. In this section, the RFB was employed to dry powder coating piroxicam
pellets to modulate immediate release with Eudragit® EPO. PEG400 was selected as a
liquid plasticizer. The effect of coating level was also investigated. The performance and
the appearance of the Eudragit® EPO coated piroxicam pellets was checked both
qualitatively and quantitatively based on scanning electron microscope (SEM) and
in-vitro release testing, respectively.

5.1.2. Effect of coating level
The immediate release coating formulations in this chapter followed the composition
showed in Table 5.1. The mass proportion of Eudragit® EPO was 10%, which was based
on the previous work done by our research group. A high mass proportion of Eudragit®
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EPO can increase the film softness and achieve a dense coating film. However, this may
also lead to the sticky coating film and agglomeration of pellets. In addition, talc and
colloidal silicon dioxide were served as anti-adherent agents in case of sticky film that
may cause agglomeration during coating process. An orange dye was added to help to
observe the film formation in an easier and clearer way.

Table 5.1 Coating fomulation composition of Eudragit® EPO polymers
Formulation

Composition (wt%)

Eudragit EPO

®

10.0

Talc

89.0

Colloidal silicon dioxide

0.5

Orange dye

0.5

The coating level (%) of the coated pellets was defined as the weight gain of coated
pellets over the weight of uncoated pellets, as shown in the following equation:

Coating level (%) =

weight of coated pellets - weight of uncoated pellets
* 100%
weight of uncoated pellets

In order to study the effect of coating level, the piroxicam pellets were coated at two
coating levels, the lower coating level is 8.82% and the relatively higher coating level is
19.9%. The scanning electron microcopy (SEM) was employed to observe the surface
and cross section of the Eudragit® EPO coated piroxicam pellets. The SEM monographs
of the high coating level pellets (19.9%) is shown in Figure 5.1. It can be seen that after
curing for 120 min under a temperature of 50 oC, the coating materials has formed a
uniform and smooth film (Figure 5.1A), wherein the boundaries between the coating
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particles no longer exist. Figure 5.1B indicates the cross section of the coated pellets. It
can be clearly observed that the uncoated piroxicam pellets were covered by a dense
coating film. This proves that the Eudragit® EPO coating film performs a continuous and
dense structure. Furthermore, from the SEM monographs, it suggests that this coating
material is able to achieve a relatively strong and smooth coating film with the RFB.
A

B

®

o

Figure 5.1 SEM micrographs of Eudragit EPO coated piroxicam pellets curing at 50 C,
120 min, RFB rotating speed: 20 rpm, coating level of 19.9%:(A) surface, (B) Cross section

The effect of Eudragit® EPO coating level on the drug release profiles is shown in Figure
5.2. The Eudragit® EPO coated piroxicam pellets were processed under a temperature of
50 oC and cured for 120 min. As can be seen from the release profiles (Figure 5.2), both
the coated pellets were released up to 90% within 20 min and achieved 100% within 60
min. This indicated that no significant effect was influenced by these two coating levels.
The reason for this is that Eudragit® EPO is a water soluble polymer and is able to
dissolve in solutions with a pH below 5.5, so the higher coating level may only extend the
dissolution of the coating film that is relatively short compared to the release of the drug
core[3]. The drug release of the Eudragit® EPO coated pellets is erosion controlled.
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®

Figure 5.2 The effect of Eudragit E PO coating level on drug release profiles.
o

(Curing temperature: 50 C, curing time: 120 min, RFB rotating speed: 20 rpm)

In solvent-based coating methods, the coating level of Eudragit® EPO coated pellets is
generally around 20%. Herein, the pellets using RFB with dry powder coating technique
can modulate immediate release with the same coating material at a relatively low
coating level (8.82%). This improvement not only reduces the usage of coating materials
but also reduces the processing time significantly. Also, the coating film achieved by the
RFB was smooth, uniform and dense according to the SEM monographs.
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5.2. Sustained release coating with Eudragit® RS/RL
5.2.1. Introduction
Sustained release is defined as a system that allows the drug to be released over an
extended period of time to achieve prolonged therapeutic effect after oral administration.
Eudragit® RL and Eudragit® RS are two commonly used coating materials for sustained
release coating. Both two coating materials comprise of ethyl acrylate, methyl
methacrylate and a small amount of methacrylic acid ester with quaternary ammonium
groups (trimethyl-ammonioethyl methacrylate chloride) that function as salts to assure
the permeability of the film.
Previous study done by our research group has proved that dry powder coated piroxicam
pellets were able to modify sustained release with the same coating materials by the
rotating pan coater[10]. In this section, the RFB was investigated to coat piroxicam
pellets with Eudragit® RL and Eudragit® RS to modulate sustained release, and TEC was
a suitable liquid plasticizer for these polymers. Two main factors influencing the
sustained release profile were studied, the effect of coating level and the ratio of
Eudragit® RS to Eudragit® RL. The performance and the appearance of the Eudragit®
RS/RL coated piroxicam pellets was studied both qualitatively and quantitatively based
on scanning electron microscope (SEM) and in-vitro release testing, respectively.

5.2.2. Effect of coating level
In this section, Eudragit® RS/RL (1:1) was selected to investigate the effect of coating
level. The overall composition of the sustained release coating formulations is shown in
Table 5.2 wherein the sum of Eudragit® RS and Eudragit® RL was 80.0%. The remaining
20% was additives including talc and colloidal silicon dioxide and a blue dye. The talc
and colloidal silicon dioxide served as the anti-adherent agent. The blue dye is an
insoluble dye aiming at a better observation of film formation. The section of the mass
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proportion of Eudragit® RS and Eudragit® RL (80%) was in accordance with previous
study done by our research group, wherein this percentage would not cause
agglomeration of the pellets and was high enough to form a strong coating film as well.

Table 5.2 Overall coating fomulation composition of Eudragit® RS and Eudragit® RL polymers
Formulation
®

Composition (wt%)
®

Eudragit RS and Eudragit RL

80.0

Talc

19.0

Colloidal silicon dioxide

0.5

Blue dye

0.5

In the plasticizer powder coating technique, the plasticizers are functionalized by
incorporating themselves between the polymers chains, which increases the free volume
and thus the Tg can be decreased dramatically[12-14]. The film formation is achieved by
the deformation and viscous flow of the plasticized-coating materials. The scanning
electron microscope (SEM) was employed to observe the film formation of the coating
materials and the effect of the coating level. Three coating levels were investigated. As
shown in Figure 5.3, the surface and cross section of the Eudragit® RS/RL (1:1) coated
pellets under different coating levels were observed. Obviously, as the coating level
increased, the smoothness of the Eudragit® RS/RL coating film became more even
(Figure 5.3A B and C). Specifically, the surface of the lowest coating level (9.23%)
coated pellets still exhibited some ‘scaly structure’, which indicated the non-uniformity
of the coating film. This was because the amount of coating materials was not enough to
form a thick and dense coating film. This phenomenon was improved simply by
increasing the coating level, which was illustrated through the coated pellets with coating
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levels of 13.13% and 17.88%. The surface of the pellets with the highest coating level
(Figure 5.3C) showed the smoothest and most uniform coating film, where the ‘scaly
structure’ no longer appeared and the coating materials were well cured continuously.
The cross section SEM micrograph of pellets with the highest coating level (Figure 5.3D)
can proved the uniform and dense coating as well. The piroxicam pellet was evenly
covered with a constant thickness (50 µm) of coating film. As a result, it can be
concluded that using the RFB dry powder coated piroxicam pellets with Eudragit®
RS/RL were able to achieve a continuous and uniform coating film. With better film
formation was obtained at a higher coating level.

A

B

C

D

®

Figure 5.3 SEM micrographs of Eudragit RS/RL(1:1) coated piroxicam pellets curing at
o

50 C, 120 min, RFB rotating speed 20 rpm: (A) Coating level of 9.23%, (B) Coating level
of 13.13%, (C) Coating level of 17.88%, (D) Cross section of coating level 17.88% pellets
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Figure 5.4 The effect of Eudragit® RS/RL coating level on drug release profiles. (Eudragit

®

o

RS/RL (1:1), Curing temperature: 50 C, curing time: 120 min,RFB rotary speed: 20 rpm)

The effect of coating level on drug release profiles is illustrated in Figure 5.4, where in
the pellets were coated with Eudragit® RS/RL (1:1) in the RFB at three different coating
levels. It is clearly shown from the release profile that the cumulative release of drug
decreased as the coating level increased, which corresponded to the performances of the
SEM monographs above as well. The coated pellets with the lowest coating level (9.23%)
showed the fastest release rate compared to the other two coating levels. It can be seen
that 90% of drug released before 3 h and the rest drug continually released to 100% from
3 h to 6 h. In addition, the coated pellets with coating level of 13.13% and 17.88%
released to 85% and 59% drug after 12 h, respectively. The release profiles of these two
coating levels behaved lineraly, which indicated the constant release rates. Theoretically,
in terms of sustained release, the appearance of the cracking films relates to the
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mechanical stability of coating films and the hydrostatic pressure[73]. When the pellets
contact with the release medium, a hydrostatic pressure will generate in the coated pellets.
At the point that the hydrostatic pressure is over the mechanical stability of the coating
film, the cracking happens. As a result of this, it is shown that the release profile of the
lowest coating level (9.23%) performed a film cracking behavior, where the coating film
cannot withstand the hydrostatic pressure generated inside the pellets. After the film
cracking, the drug release was no longer controlled by the Eudragit® RS/RL coating film;
instead, it was dominated by the diffusion through water. Thus, the release rate was much
faster compared to those Eudragit® RS/RL coating film controlled release profiles
(coating level of 13.13% and 17.88%). This indicates that for sustained release, pellets
with low coating level has a different release mechanism from the higher coating level
ones, wherein the former one is erosion control and the latter one is diffusion control.

5.2.3. Effect of ratio between Eudragit® RS and Eudragit® RL
As has been introduced in Chapter 2.3.3, Eudragit® RS and Eudragit® RL have different
permeability due to the amount of their quaternary ammonium groups. Since Eudragit®
RL has double content of the function groups, it is more permeable. As a result of this, it
can be imagined that Eudragit® RL coated pellets perform a relatively high drug release
rate compared to Eudragit® RS. Therefore, the adjustment of the ratio between the two
polymers would influence the control of release rate to some extent. Three formulations
of the Eudragit® RS/RL (1:2, 1:1, 2:1, mass ratio) under two different coating levels were
investigated by the RFB with dry powder coating technique to study the effect on
sustained release.
Scanning electron microscope (SEM) was employed to observe the surface of the
different Eudragit® RS/RL ratio coated pellets with a coating level of 18%. The surface
and cross section condition were shown in Figure 5.5. It can be seen that from Figure
5.5A,B and C, after curing for 2 h, both the three coating formulations (Eudragit® RS/RL
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1:2, 1:1, 2:1) formed continuous and dense coating films, where the boundaries between
particles disappeared and the thickness of the coating film was uniform (around 50 µm).
Moreover, it was shown in Figure 5.5D that the boundary between the uncoated
piroxicam pellet and the Eudragit® RS/RL coating film was clearly illustrated. It also
A

B

C

D

®

o

Figure 5.5 SEM micrographs of Eudragit RS/RL coated piroxicam pellets curing at 50 C,
®

120 min, RFB rotary speed: 20 rpm, coating level of 18%: (A) Eudragit RS/RL(1:2), B)
®

®

®

Eudragit RS/RL(1:1), (C) Eudragit RS/RL(2:1), (D) Cross section of Eudragit RS/RL(2:1)

indicated the formation of a strong and dense Eudragit® RS/RL coating film.
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Figure 5.6 The effect of Eudragit® RS and Eudragit® RL ratio on drug release profiles. (Curing
o

temperature: 50 C, curing time: 120 min, RFB rotary speed: 20 rpm, coating level: 9.0%)

The effect of the polymer ratio (Eudragit® RS/RL) on drug release profiles is shown in
Figure 5.6 and Figure 5.7. In Figure 5.6, the dry powder coated piroxicam pellets in RFB
with a low coating level (9.0%) demonstrated no obvious effect due to adjusting the
polymer ratio. All of the three formulations coated pellets released to 90% within the first
4 h and gradually reached 100% at 10 h. There was a slight tendency between the three
release profiles. Pellets coated with Eudragit® RS/RL (1:2) had a faster release rate than
the other two formulations, where it only took 2 h to release 90% of drug. Pellets coated
with Eudragit® RS/RL (1:1, 2:1) released relatively slower, in which the 1:1 coated
pellets released to 90% of the API at 3 h and the 2:1 ones took 3.25 h. Reason for this is
that since the pellets coated with Eudragit® RS/RL (1:2) has a higher ratio of Eudragit®
RL, the release rate, from previous work that Eudragit® RL has a high permeability and
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limited swellability, and was thus faster than the other two formulations with lower
Eudragit® RL content. Moreover, the reason of the fast release within a short time (4 h) is
the film cracking behavior. As mentioned in the above section, the coating film cannot
withstand the hydrostatic pressure generated inside the pellets since the coating level is
relatively low. After film cracking, the drug release was no longer controlled by the
Eudragit® RS/RL coating film; instead, it was dominated by the diffusion through water.
Moreover, the release rates were quite fast at the first 3 h but suddenly reduced to slow
rates after 3 h. This was mainly attributed to the relatively low coating level (9.0%). At a
low coating level, coating materials attached to the surface of the pellets were not enough
to form a strong and dense coating film, which results in weak coalescence between
polymer molecules and cracking behavior within a short time.
The effect on drug release profiles of the polymer ratio at a higher coating level was
shown in Figure 5.7. It was observed that for the pellets with a coating level of 18.0%,
the drug release rate decreased dramatically as the weight ratio of Eudragit® RS increased.
This denotes that by adjusting the ratios between the two polymers, the release profiles
can be controlled at a wide range. Specifially, the Eudragit® RS/RL (1:2) coated pellets
had a cumulative release of 72% after 12h, and the Eudragit® RS/RL (1:1) coated pellets
released to 59% of drug after 12h, whereas the Eudragit® RS/RL (2:1) coated pellets only
reached 38% of the cumulative release in the same time interval. As mentioned before,
this was attributed to the permeability difference of Eudragit® RS and Eudragit® RL,
where a higher content of Eudragit® RL performed the fastest release rate and a lower
Eudragit® RL content behaved a slowest release rate. Besides, all of the three release
profiles of the coated pellets at high coating level (18%) demonstrated proportional lines,
which suggested the release of the drug remained at a constant rate and was controlled by
the Eudragit® RS/RL coating film. Reason of this was that a higher coating level
provided a thicker and more uniform coating film, which had a better control of the
release profile. Theoretically, since the coating film was denser compared to the low
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coating level one, the mechanical stability was strong enough to sustain the hydrostatic
pressure generated in the coated pellets when immersed in the release media, thus the
drug release was controlled by the coating film.

Figure 5.7 The effect of Eudragit® RS and Eudragit® RL ratio on drug release profiles. (Curing
o

temperature: 50 C, curing time: 120 min, RFB rotating speed: 20 rpm, coating level: 18.0%)
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5.3. Delayed release coating with Acryl-EZE
5.3.1. Introduction
Delayed release refers to the system formulated to release the API at a delayed interval
rather than release immediately after oral administration. The coating materials used for
delayed release are pH dependent, which means they are acid resistant but, will
decompose in solutions with high pH value. Also, delayed release is aimed at preventing
the API from irritating the stomach, protecting the degradation of the solid dosage forms
under the low pH environment of stomach and targeting the API absorption to a portion
of the intestinal tract beyond the stomach. One of common used coating materials to
modulate delayed release is Acryl-EZE. It is a full formulation coating material with the
effective component Eudragit® L 100-55. Acryl-EZE is degradable when the pH value of
the media is above 5.5, and thus it is applied to release the API at the first section of
small intestine.
Previous work done by our research group reported that the dry powder coated
Acryl-EZE pellets achieved by rotating pan coater were able to modulate delayed release
successfully[12]. Therefore, in this section, the RFB was employed for the coating of
Acryl-EZE with dry powder coating technique to modulate delayed release, and PEG 400
served as a suitable liquid plasticizer. The effect of coating level was investigated. Notice
that the effects of curing time and curing temperature were also studied and will be
discussed in Chapter 6.2 and 6.3 (since the curing time and curing temperature also
related to the process conditions of the RFB and thus will be reported in Chapter 6).
In-vitro release testing and scanning electron microscope (SEM) were employed to study
the release profile and appearance of the Acryl-EZE coated pellets.

5.3.2. Effect of coating level
As Acryl-EZE is a full-formulation coating material, blue dye was added into the
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formulation for better observation of the film formation (shown in Table 5.3).
Table 5.3 Coating fomulation composition of Acryl-EZE polymers
Formulation

Composition (wt%)

Acryl-EZE

99.5

Blue dye

0.5

The scanning electron microscope (SEM) micrographs were employed to observe the
film formation of the Acryl-EZE coated pellets, as shown in Figure 5.8. Compared with
the surface of uncoated piroxicam pellets (Figure 5.8A), the Acryl-EZE coated ones
(Figure 5.8B) performed a uniform and smooth coating film. The uneven surface of the
uncoated pellets no longer existed, which indicated that the piroxicam pellets were fully
covered with a dense and continuous Acryl-EZE coating film. Also, the surface uniform
smoothness of the high coating level (21.93%) coated pellets denoted the well curing of
the Acryl-EZE coating materials. As a result, from the SEM micrographs, the Acryl-EZE
dry powder coated pellets were able to achieve a smooth and dense coating film in the
RFB.

A

B

Figure 5.8 SEM micrographs of Acryl-EZE coated piroxicam pellets curing at
o

50 C, 120 min, RFB rotating speed 20 rpm: (A) Uncoated piroxicam pellet,
(B) Surface of coated pellets with coating level of 21.93%
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In terms of enteric coating, the most important standard to balance whether the coating is
qualified is the acid resistance test. It is characterized by the cumulative drug release
percentage in 0.1N HCl media after the first 2 h. According to the United States
Pharmacopoeia (USP) <711>, the standard of delayed release coating is obliged to be less
than 10% of the cumulative drug release in the acid media after the first 2 h.

Figure 5.9 The effect of Acryl-EZE coating level on drug release profiles.
o

(Curing temperature: 50 C, curing time: 120 min, RFB rotating speed: 20 rpm)

The effect of Acryl-EZE coating level on drug release profiles was performed in Figure
5.9, where three selected coating levels, from low to high, were investigated. As shown in
Figure 5.9, all of the release profiles of the coated pellets showed a ‘delayed release’, in
which little API released within the first 2 h. The lowest coating level (10.84%)
performed an acid resistance of 16.6% cumulative release after the first 2 h, and the
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pellets with higher coating levels of 13.25% and 21.93% showed 8.5% and 6.6%
cumulative release, respectively. Both the coated pellets of three coating levels released
immediately after adjusting the release media from pH 1.2 to pH 6.8 through the addition
of 0.2 M tribasic sodium phosphate solution. Therefore, the pellets with the coating level
of 10.84% was unqualified based on the standard of USP <711>, which released more
than 10% after 2 h in pH 1.2 acid media. It showed that the pellets with higher coating
levels (13.25% and 21.93%) could meet the pharmaceutical standard. It was obvious that
increasing the coating level showed better acid resistance of the coated pellets and gave
better release profiles. This is because the amount of the coating materials attached onto
the low coating level pellets surface, compared to pellets with higher coating levels, were
not enough to form a uniform and continuous coating film. This may lead to weakness of
coalescence between polymer molecules during curing procedure and reduction of the
coating film intensity, and finally result in the cracking effect of the coating film in the
drug release test. Similarly, for high coating level coated pellets, a strong and uniform
coating film was obtained, which performed a good control of the delayed release
profiles.
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6.

Chapter 6
Optimization of Process Conditions

6.1. Introduction
As described in the previous chapter, RFB was successfully applied to the dry powder
coating of small pellets with different coating materials (Eudragit® EPO, Eudragit®
RS/RL and Acryl-EZE) for immediate release, sustained release and delayed release,
respectively. This chapter reported the optimization of processing conditions in RFB.
Several operating factors were studied regarding curing time, curing temperature, RFB
rotating speed, liquid plasticizer spraying flowrate as well as fluidizing air flowrate.
Acryl-EZE was selected as the example coating material to optimize the coating
conditions.
According to the United States Pharmacopoeia (USP) <711> standard, the delayed
release coated pellets have to be less than 10% of the cumulative drug release in the acid
media after the first 2 h in the in-vitro drug release tests. For the Acryl-EZE coated
piroxicam pellets, the process conditions can be optimized based on this standard. This
indicates that the coated pellets with a cumulative release less than 10% after the first 2 h
can be regarded as qualified, while those with a cumulative release more than 10% after
the first 2 h did not achieve standard request. Both in-vitro drug release testing and the
scanning electron microscope (SEM) were employed to study the effects of the process
conditions.

6.2. Effect of curing time
In dry powder coating process where most of the coating polymers belong to
thermoplastic polymers, film formation occurs once the deformation and viscous flow of
the coating polymer particles happen when the curing temperature is above the glass
transition temperature (Tg) of the coating polymers[65]. The viscosity of the coating
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materials decreases as the temperature increases, resulting in the deformation of particles.
The coalescence of the coating particles requires enough time to form a coating film.
Therefore, both the curing time as well as the curing temperature results in significant
influences on the film formation of the coating materials.
A

B

C

D

Figure 6.1 SEM micrographs of Acryl-EZE coated piroxicam pellets curing
o

at 50 C, RFB rotating speed 20 rpm: (A) 0 h, (B) 1 h, (C) 1.5 h, (D) 2 h

First, the effect of curing time was shown with the three intervals (1 h, 1.5 h, 2 h) at three
temperatures, 30 oC, 40 oC and 50 oC. SEM was employed to investigate the effect of
curing time on film formation. As shown in Figure 6.1, the Acryl-EZE coated pellets
curing under 50 oC illustrated that before the curing started, the individual coating
particles were clearly seen and the boundaries between the particles were distinctly
observed, indicating that the coating particles were non-fused and the curing did not start
immediately after the powder deposition (Figure 6.1A). After 1 h of curing, the particles
began to coalesce with each other and form a smooth film, while the surface of the coated
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pellets were still characterized by some voids and non-fused coating particles, and the
boundaries between the particles were still visible (Figure 6.1B). As the curing time
increased to 1.5 h (Figure 6.1C), most of the coating particles coalesced with no visible
particle boundaries observed, denoting that a dense coating film was formed. After
another half hour of curing (total curing for 2 h) (Figure 6.1D), the entire pellet was
covered with a smooth and continuous coating film and the particles were no longer observed.
As mentioned above, the addition of the liquid plasticizer can decrease the Tg
significantly, and when the processing temperature is above the Tg, the film formation
can be achieved based on the deformation and viscous flow of the coating materials. The
film formation requires a period of time to accomplish; as a consequence, increasing the
curing time can help to strengthen the acid resistance of the coated pellets effectively
when the curing temperature is closed to/above the Tg of the coating polymers.

Figure 6.2 The effect of curing time on drug release profiles. (Coating material:
o

Acryl-EZE, Curing temperature: 30 C, RFB rotating speed: 20 rpm)
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The effect of curing time on drug release profiles were studied under three temperatures.
From the pellets coated under 30 oC (Figure 6.2), it is shown that the drug release profiles
of the pellets with 1 h, 1.5 h and 2 h curing time performed 85 %, 70 % and 31 %
cumulative release after the first 2 h in 0.1 N HCl pH 1.2 acid media. Obviously, this
indicates the acid resistance of the coated pellets increased dramatically when the curing
time was extended from 1 h to 2 h. The reason for this is that the film formation of the
longer curing time pellets allowed better coalescence compared to the short time cured
pellets, and thus the longer curing time coated pellets exhibited a lower cumulative drug
release after the first 2 h. However, under the temperature of 30 oC, all coated pellets with
three curing times were unqualified due to the high cumulative release that were above
10%, based on the USP <711> standard. This is because the curing temperature of this
condition was 30 oC, which didn’t reach the Tg of the coating material. Under this
condition, the coating films of the pellets were weak and the molecules of the coating
material were not fully coalesced with each other, and thus happened to crack when
contacted with the release media and result in the unqualified drug release profiles.
Figure 6.3 shows the effect of curing time on drug release profiles at the temperature of
40 oC. Similarly, the acid resistance of the coated pellets increased as the curing time
adjusting from 1 h to 2 h. The cumulative release of the coated pellets after the first 2 h
with the curing time of 1 h, 1.5 h and 2 h were 28 %, 24 % and 19%, respectively.
However, both the pellets under this condition were not qualified according to the USP
<711> standard.
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Figure 6.3 The effect of curing time on drug release profiles. (Coating material:
o

Acryl-EZE, Curing temperature: 40 C, RFB rotating speed: 20 rpm)

The effect of the curing time on drug release profiles of the Acryl-EZE coated pellets
under 50 oC were shown in Figure 6.4. As can be seen, all of the pellets coated with the
three curing time performed a cumulative release less than 20%. The cumulative release
of the coated pellets after the first 2 h with the curing times of 1 h, 1.5 h and 2 h were
15 %, 9 % and 8%, respectively. According to the USP <711> standard, the pellets with
curing time of 1.5 h and 2 h were qualified. Clearly, increasing the curing temperature
can give a better performance of the acid resistance under this condition. As explained
above, this is because the curing temperature of 50 oC was very close to the Tg of the
plasticized coating polymer, which helped the better film formation. Furthermore, the
pellets coated under these conditions performed very ideal delayed release profiles. The
Acryl-EZE coating film can control the release of the API accurately and further proved
the complete film formation of the coating materials in the RFB.
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Figure 6.4 The effect of curing time on drug release profiles. (Coating material:
o

Acryl-EZE, Curing temperature: 50 C, RFB rotating speed: 20 rpm)

6.3. Effect of curing temperature
As mentioned above, in the coating process using the RFB with the plasticizer powder
coating technique, the deformation and viscous flow of the coating polymer particles
generates the film formation process when the curing temperature is close to/above the
glass transition temperature (Tg) of the coating polymer[65]. Therefore, apart from the
curing time, the curing temperature is another key factor that has significant influence on
the film formation of the coating materials. The effect of the curing temperature was
investigated for pellets coated at the temperature of 30 oC, 40 oC, and 50 oC curing for 2 h.
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A

B

C

Figure 6.5 SEM micrographs of Acryl-EZE coated piroxicam pellets curing for 2 h,
o

o

o

RFB rotating speed 20 rpm: (A) 30 C, (B) 40 C, (C) 50 C

The effect of curing temperature on film formation was investigated using SEM, as
shown in Figure 6.5. Obviously, both the SEM micrographs of the coated pellets curing
at 30 oC and 40 oC exhibited an incomplete coating film, where the coating particles were
still visible and a small portion of the particles were non-fused (Figure 6.5A and Figure
6.5B). When the curing temperature was increased to 50 oC that is closer to the Tg of the
coating polymer, a uniform and continuous coating film was obtained (Figure 6.5C).
Under the temperature of 50 oC, the coating particles were fused completely and
coalesced with each other. There were no individual particles observed at this
temperature. Compared to the coated pellets cured under 30 oC and 40 oC, the 50 oC one
showed the best film formation. As mentioned above, the viscous flow and deformation
starts when the temperature is close to/above the Tg of the coating materials, as a
consequence, the best film formation can only be achieved when the curing temperature
reaches the Tg of the coating materials.
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Figure 6.6 The effect of curing temperature on drug release profiles.
(Coating material: Acryl-EZE, Curing time: 2 h, RFB rotating speed: 20 rpm)

The effect of the curing temperature on drug release of the coated pellets is shown in
Figure 6.6. Similar to the above results shown by the SEM micrographs, the acid
resistance of the coated pellets was improved as the curing temperatures increased from
30 oC to 50 oC. Specifically, the cumulative release of the coated pellets after the first 2 h
was 30 %, 19 % and 8 %, which correspond to the curing temperature of 30 oC, 40 oC and
50 oC, respectively. According to the USP <711> standard, only the pellets with the
curing temperature of 50 oC were qualified because its cumulative release were under 10%
during the first 2 h in 0.1N HCl solution. The reason for this is that only when the curing
temperature is closed to or above the Tg of the coating polymer, the deformation and
viscous flow of the coating particles could happen. And for the pellets cured at 30 oC and
40 oC, the curing temperatures were far away from the Tg, which resulted in the
uncompleted film formation and unqualified acid resistance performance.
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6.4. Effect of the RFB rotating speed
As described in Chapter 4, the RFB is equipped with a unique structure. It contains a
rotatable cylindrical tank that consists of the inner layer and the outside layer, wherein
the inner layer is covered with porous material (mesh) and the outer layer is made of
acrylic. There are six chambers located between these two layers, and three of them serve
as the inlets and outlets of the fluidizing air alternately when the cylindrical tank is
rotating during the process. Adjusting the rotating speed of the RFB during the coating
process may affect the inlet of the fluidizing air, the centrifugal force of the loaded pellets
and the adhesion force between the coating materials and the pellets. All of these may
affect the film formation of the coating process. Therefore, the control of the rotating
speed has become one of the major factors that may have influence on the coating
process.
In this section, three rotating speed of the RFB were selected, including a relatively low
speed 6 rpm, a medium speed 20 rpm and a relatively high speed 70 rpm. In fact, the
RFB had a limitation of the rotating speed, which ranged from 6 rpm to 75 rpm.
Moreover, when the rotating speed was above 70 rpm, a short circuit would happen. This
means that the pellets would attach to the wall of the cylindrical tank due to the large
centrifugal force generated from the fast rotating speed. The in-vitro drug release test was
employed to study the effect of the RFB rotating speed.
The effect of the RFB rotating speed was illustrated by the drug release profiles of the
Acryl-EZE coated pellets, as shown in Figure 6.7. It is obviously that the drug release
profile of the coated pellets with a rotating speed of 20 rpm exhibited the lowest
cumulative release (8%) after the first 2 h in the 0.1 N HCl media. The pellets with a high
rotating speed (70 rpm) showed a slightly higher cumulative release (13%) after the first
2 h. Compared to the two higher rotating speeds, the pellets with a rotating speed of 6
rpm had the highest cumulative release value (29%). According to the USP <711> drug
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Figure 6.7 The effect of RFB rotating speed on drug release profiles.
o

(Coating material: Acryl-EZE, Curing temperature: 50 C,Curing time: 2 h,)

release standard of delayed release, only the 20 rpm one was qualified, and the pellets
with 70 rpm rotating speed was slightly higher than the standard. This is because under
the low rotating speed (6 rpm), the relatively slow movement of the pellets was not
beneficial to the formation of a uniform and smooth coating film. The coating materials
may attach to each other before deposit on the surface of the pellets and the coating
efficiency decreased. A relatively high rotating speed may generate strong centrifugal
force of the pellets and the coating particles, and also lead to the strong tumbling of the
pellets. This will result in the attachment of both the pellets and the coating particles on
the wall. Moreover, as the adhesion of the coating particles may block the pores of the
porous mesh, it could be difficult for the moisture to exit which may lead to the sticky
coating film and bad performance on the drug release profiles.
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As a consequence, the rotating speed of the RFB should be maintained at an appropriate
range (around 20 rpm) where the pellets in the RFB are coated under moderate
conditions.

6.5. Plasticizer spraying flowrate
As mentioned in Chapter 2.3.5, in plasticizer powder coating technique, the plasticizers
addition can help to solve the problem of the brittle coating film generated from pure
coating polymers. In the coating process in the RFB, plasticizers are functionalized by
incorporating themselves between the polymers chains and increase the free volume, thus
the Tg of the coating materials can be decreased dramatically[12-14]. Moreover,
plasticizers also function as increasing the capillary force between the coating polymers
and the surface of the pellets, which enhance the powder adhesion on the pellet surface
and eventually increase the efficiency of coating process[12-14]. A suitable selection of a
plasticizer and a accurate addition amount thus become two critical points. Since the
suitable plasticizer (PEG 400) for Acryl-EZE has already been investigated by our
research group, the appropriate amount of the liquid plasticizer in the RFB coating
process requires further investigation.
The plasticizer addition amount is based on the spray time and flowrate. The spray time
has to be matched with the coating material feed amount and plasticizer flowrate, and
thus the latter factor is a key point that decides the success of the coating process in the
RFB. This is because firstly, small spraying flowrate leads to a poor powder adhesion
effect and further film formation is uncompleted. It will produce a brittle, discontinuous
coating film and fails in the in-vitro drug release test. In contrast, large flowrate means
excessive amount of liquid plasticizers addition immediately and may lead to a sticky
problem. As a result, it is of great importance to find an appropriate spraying flowrate
that can generate a uniform and strong coating film as well as avoid the sticking problem.
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o

Figure 6.8 Photos of Acryl-EZE coated piroxicam pellets curing for 2 h, 50 C,
RFB rotating speed 20 rpm: (A) 0.15 g/min, (B) 0.25 g/min, (C) 1.0 g/min

Acryl-EZE was selected as the coating material and PEG 400 was a suitable liquid
plasticizer of this polymer as mentioned before. The loading of the piroxicam pellets was
40 g/batch. As shown in Figure 6.8, three spraying flowrates of the liquid plasticizer were
selected, including a relatively low one 0.15 g/min, a medium one 0.25 g/min and a
relatively high one 1 g/min (spraying time was 30-40 s every time before the coating
material feeding each time). Obviously, the pellets coated with a spraying flowrate of
0.15 g/min showed a non-uniform coating film, where the color of the coated pellets was
not uniform, some were almost white while others were blue (Figure 6.8A). The coated
pellets with a medium spraying flowrates (0.25 g/min) exhibited a relatively uniform
appearance of the coating film (Figure 6.8,B). The coated pellets with the relatively high
plasticizer spraying flowrate (1 g/min) had the deepest blue color compared to the
previous two (Figure 6.8,C). Also, it can be clearly seen that some pellets were attached
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to each other and generated ‘twins’, which indicated the sticky problem of the coating
film due to the excessive amount of the liquid plasticizer.
Moreover, the in-vitro drug release test of the Acryl-EZE coated pellets at the plasticizer
spraying rates of 0.15 g/min and 1 g/min were failed. This is because the low spraying
flowrate leads to a small amount of plasticizer on the pellets surface thus further decrease
poor powder deposition effect, and thus the coating film was brittle and thin. And the
high spraying flowrate leads to the ‘twins’ effect, which may result in the break that
appears at the edge between the ‘twins’ when immersed into the drug release media.
From the above results, the most suitable spraying rate of the liquid plasticizer in the RFB
dry powder coating process is around 0.25 g/min. At this spraying flowrate, the coating
film performed continuous, smooth and dense appearance and the drug release test in
Chapter 5.3 were qualified. Moreover for the other two kinds of coating materials
(Eudragit® EPO, Eudragit® RS/RL), this was also the appropriate plasticizer spraying rate
and the drug release profiles showed good performance to modulate immediate release,
and sustained release as well.

6.6. Fluidizing air flowrate
As described in Chapter 4.1.1, the fluidizing air is introduced into the RFB during
processing. It not only helps the mixing of the coated pellets and the coating materials,
but also works as the temperature controller in the RFB coating system. Thus, the
fluidizing air is an essential part of the RFB coating system. Specifically, the flowrate of
the fluidizing air introduced in the cylindrical tank is important during the whole process,
which means that it has to be controlled at an appropriate flowrate, neither too small nor
too large.
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During the experiment, it has been found that a small flowrate may lead to long
preheating time as well as poor control of the temperature in the RFB, and the pellets
tended to be sticky since the small fluidizing air was not sufficient to ‘separate’ the
‘twins’. In contrast, a large flowrate may blow away the coating materials before they
deposited on the surface of the pellets and failed to form a strong coating film. It also
resulted in a thin coating film and a low coating efficiency of the coating process. The
following equation can be employed to calculate the actual flowrate of the inlet fluidizing
air of the RFB, where the subscript ‘actual’ refers to the actual operating conditions, and
the subscript ‘reading’ refers to the value read from the flowmeter and pressure gage.

Qactual = Qreading

PreadingTactual
PactualTreading

From the experiment, the actual flowrate (Qactual L/min) of the inlet fluidizing air was
around 35 L/min, which was the most appropriate flowrate employed during the coating
process.
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7.

Chapter 7

Comparison of Rotary Fluidized Bed, Rotating Pan Coater
and Traditional Fluidized Bed
7.1. Introduction
In this chapter, the performance of RFB is compared with two typical pharmaceutical
coating apparatus, a rotating pan coater and a traditional fluidized bed (top-spray. The dry
powder coating technique was employed to investigate the comparison among the three.
The comparison was examined in the following two aspects, process conditions and
coating results.

7.2. Process conditions
Acryl-EZE and PEG 400 were selected as the coating material and liquid plasticizer to
investigate the comparison of process conditions between the RFB, a rotating pan coater
and a traditional fluidized bed. The process conditions include pellets loading amount,
coating materials feeding amount, plasticizer flowrate, curing temperature, curing time,
fluidizing air flowrate, ideal coating level, coating level and coating efficiency, as shown
in Table 7.1. The equations to calculate the target coating level, coating level and coating
efficiency are as follows:

Ideal coating level (%) =

Coating level (%) =

coating materials feeding amount
* 100%
weight of uncoated pellets

weight of coated pellets-weight of uncoated pellets
* 100%
weight of uncoated pellets

Coating efficiency (%) =

coating level
* 100%
ideal coating level
84

Table 7.1 Comparison of process condition
Rotary fluidized

Rotating pan

Traditional

bed

coater

fluidized bed

Pellets loading amount (g)

40

70

70

Coating materials feeding amount (g)

6.5

12

12

Plasticizer flowrate (g/min)

0.25

0.88

1

Curing time (h)

2

2

2

Curing temperature ( C)

50

50

40

Fluidizing air flowrate (L/min)

35

-

155

Ideal coating level (%)

16.3

16.7

16.7

Coating level (%)

9

11

6

Coating efficiency (%)

55

66

36

o

It was shown that the RFB has the smallest pellets loading amount (40g). In the rotating
pan coater and traditional fluidized bed, the loading amount is 70g. Coating material
feeding amount and plasticizer flowrate depended on the powder deposition condition
during the coating process and the pellets loading amount. In addition, the curing
temperature of traditional fluidized bed (40 oC) was lower than the other two (50 oC), and
this is because the large fluidizing air (155 L/min) introduced in the tradition fluidized
bed limits its heating ability and accurate control of the temperature. Moreover, the
coating efficiency of the pellets coated in the three coating systems indicates the
deposition amount of coating materials on the pellets surface, which further influenced
the film formation. Specifically, when the ideal coating levels were the same and the
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pellets were coated under similar conditions among the three apparatus, the rotating pan
coater had the largest coating efficiency (66%), the RFB ranked in the middle (55%) and
the traditional fluidized bed had the smallest coating efficiency (36%). This was mainly
related to the flowrate of the fluidizing air in the systems. Since there was no fluidizing
air in the rotating pan coater system, the coating materials stayed in the rotating pan
coater and continuously attached to the pellets, therefore it had the highest coating
efficiency. While for the RFB and traditional fluidized bed, the introduced fluidizing air
may have a chance to blow away the coating materials that already attached or not
deposited on the pellets surface, which may result in a less amount of powder deposition
on the pellets and thus lead to a lower coating efficiency. Since the traditional fluidized
bed had a larger flowrate of fluidizing air, the relating pellets exhibited the lowest coating
efficiency. This also indicates the worst usage of the feeding coating materials.
The energy consumption can be analyzed in a macroscopic view. During the coating
process in the three systems, the usage of the fluidizing air and the heating system
consumed the most energy compared to the rotation power. Since the RFB and the
traditional fluidized bed both required fluidizing air to fluidize the pellets and maintain
the temperature of the system while the rotating pan coater had no fluidizing air, it can be
concluded that the rotating pan coater had the least energy consumption, and the RFB
ranks the second, and finally the traditional fluidized bed since it required the largest
amount of fluidizing air during the process.
As a result, in terms of the process conditions, the RFB and rotating pan coater are more
suitable for the coating of pellets with dry powder coating technique in contrast to the
traditional fluidized bed. The RFB has a smaller loading amount compared to the other
two systems; however, enlarging the scale of the RFB can improve the handling ability.
And the coating efficiency of RFB is not very high, but this can be improved by the
addition of a recycling part that can collect the coating materials blown away by the
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fluidizing air. The addition of recycling part can also improve the powder deposition on
the pellets surface and thus increases the coating efficiency. In addition, the rotating pan
coater performs a relatively large loading amount and a high coating efficiency, which
indicates that it is suitable for coating of small pellets. However, the traditional fluidized
bed showed a non-ideal temperature control of the curing temperature and a really low
coating efficiency compared to the other two. Therefore, it does not have accurate
temperature control ability and may require longer time to achieve the same coating level
coated pellets than the RFB and the rotating pan coater.

7.3. Results of coating
In this section, the coating performance of RFB is compared with the rotating pan coater
and the traditional fluidized bed regarding the coating of 0.9-1.1mm piroxicam pellets
and 0.1-0.3 mm micronized microcrystalline cellulose (MCC) pellets. Scanning electron
microscope (SEM) was employed to observe the surface of the coated MCC pellets.

7.3.1. Coating of piroxicam pellets
The piroxicam pellets were coated in the RFB, the rotating pan coater and the traditional
fluidized bed followed with the process conditions shown in Table 7.1. The coating
material was Acryl-EZE and PEG 400 was the plasticizer.
The SEM micrographs of the coated pellets were exhibited in Figure 7.1, which indicated
the film formation in the three systems. It can be seen that the pellets coated in the RFB
and the rotating pan coater (Figure 7.1A and Figure 7.1B) showed a quite smooth and
uniform coating film. The coating particles were fused to form a complete and continuous
film with no boundaries of the particles observed. Compared to the above two coating
systems, the pellets coated in the traditional fluidized bed (Figure 7.1C) did not show a
smooth coating film after curing for 2 h. The surface of the coated pellets was still
characterized by some voids and the individual particles existed with their boundaries
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A

B

C

Figure 7.1 SEM micrographs of Acryl-EZE coated piroxicam pellets curing for 2 h:
(A) RFB, (B) Rotating pan coater, (C) Traditional fluidized bed

visible. Reason of this is that according to Table 7.1, the coating level and coating
efficacy of the traditional fluidized bed coated pellets was relatively low. The deposition
amount of the coating materials was relatively less and the thickness of the coating film
was not enough to cover the pellets and form a uniform and continuous coating film. Also,
since the fluidizing air introduced in the traditional fluidized bed had a large flowrate, the
strong fluidizing air may have a chance to damage the surface of the pellets and this also
caused the non-ideal film formation during the curing process. In contrast, the fluidizing
air in the RFB was quite small and mild that would not affect the film formation, and the
rotating pan coater had no fluidizing air, thus the surfaces of the pellets coated with these
two coating systems performed a more uniform and smoother coating film.
Based on the results above, the RFB presented comparable film formation quality with
the rotating pan coater while being superior to the traditional fluidized bed.
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7.3.2. Coating of micronized microcrystalline cellulose (MCC) pellets
Today, the application of the coating of small solid dosage forms with a micronized size
has become one of the popular research projects since it is very widely applied in
pharmaceutical industry. For instance, some research groups are working on coating
micronized pellets coating that are encapsulated in the capsule. This can help to control
the action site of the API more accurately. However, since the micronized pellets have a
large specific surface area and tend to agglomerate easily, the coating process is very
difficult to achieve.
In this section, the three coating apparatus were attempted to coat the micronized MCC
pellets (D=0.1-0.3mm) using dry powder coating technique. Compared to the piroxicam
pellets whose size is 0.9-1.1mm, the tiny MCC pellets not only have a small size but also
show a relatively light weight, which makes its behavior more like powders. The tiny
MCC pellets are equipped with a really high specific surface area. The coating of them
becomes more difficult since they are easy to get sticky and need much more coating
material feeding times to avoid the sticky effect as well as longer curing time to achieve a
uniform coating film compared to the larger pellets.
During the experiment, it was found that compared to the RFB and the traditional
fluidized bed, the rotating pan coater has an open system, which means that the coating
pan is not covered with a lid during the coating process. The tiny MCC pellets were easy
to be blown away by the air generated from the plasticizer-spraying nozzle, and the
pellets also dropped out all the time due to the rotation of the coating pan. These
observation suggested that the rotating pan coater was not suitable for the coating of tiny
pellets not only owing to the open system of the pan coater but also due to the light
weight of the tiny pellets. The RFB and the traditional fluidized bed performed better in
the coating of tiny MCC pellets. During the process, the RFB coated pellets were not
easy to get sticky and agglomerated with each other. This is due to the fluidizing air
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introduced in the system. The introduced fluidizing air helped the tiny pellets generate
‘gasless fluidized state’ with the help of the wall friction that came from the rotation. It
dramatically contributed to the mixing between the coating materials and the tiny pellets
and further improved the uniformity of the coated pellets.
The traditional fluidized bed also exhibited a good fluidization state with the strong
fluidizing air, and the tiny pellets, during the coating process, did not show a strong
sticky phenomenon apart from the wall part that near the plasticizer spraying nozzle. The
reason for this is that the diameter of the plasticizer sprayed from the nozzle was larger
than the size of the column of the fluidized bed, and this may lead to wetness of the wall
near the outlet of the nozzle. This phenomenon more or less lowers the coating efficiency
since the wet wall may be adhered to by a small portion of the pellets.

A

B

Figure 7.2 SEM micrographs of Acryl-EZE coated tiny MCC pellets curing for 2 h:
o

o

(A) RFB, 50 C, (B) Traditional fluidized bed, 40 C

The surface of the RFB and the traditional fluidized bed coated pellets were illustrated by
the SEM, as shown in Figure 7.2. It is clearly shown that the RFB coated tiny pellets had
a relatively complete and continuous coating film (Figure 7.2A), while there were still
come non-fused particles and additives attached on the pellets surface, and the
smoothness of the coating film was not very good due to the ‘layer by layer’ phenomenon.
Compared to the RFB coated tiny pellets, the SEM micrographs of the traditional
fluidized bed coated pellets (Figure 7.2B) performed a non-ideal coating film. And it was
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clearly illustrated that only part of the deposited coating powders were fused with voids
characterized on the pellets surface, and the boundaries between the particles still existed,
which indicated a non-uniform and in-complete coating film.
The photos of the RFB dry powder coated tiny MCC pellets (Figure 7.3B) further
indicated the coating performance. The coated pellets showed a uniform appearance with
the even color on every pellet, and the pellets were not sticky at all. Compared to the
uncoated tiny MCC pellets (Figure 7.3A), it can be concluded that the pellets were
covered with a thick and continuous coating film.

A

B

o

Figure 7.3 Photos of Acryl-EZE coated MCC pellets curing for 2 h, 50 C:
(A) Uncoated MCC tiny pellets, (B) RFB coated MCC tiny pellets

As a consequence, in terms of the performance of the coating process and film formation
effect of the tiny MCC pellets from the SEM micrographs, the RFB has the best coating
film with the lowest loss of the coated pellets, and the traditional fluidized bed was
practicable for the coating, however, the film formation of the coated tiny pellets was not
as good as the RFB coated ones. The rotating pan coater was not an appropriate selection
due to its open system. Moreover, it can be predicted that the RFB is more suitable for
the coating of tiny pellets even workable for the coating of powders owing to the unique
points of closed system and the introduce of the fluidizing air.
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8.

Chapter 8
Conclusions

A newly invented pharmaceutical coating apparatus, the rotary fluidized bed (RFB), was
applied for the pellets coating with dry powder coating technique. The RFB has a unique
structure where the uniform pellets coating is facilitated by the introduced fluidizing air
and a rotation behavior during the process. SEM micrographs indicated the complete film
formation over the entire piroxicam pellets via dry powder coating. All typical drug
release types were realized, including immediate release, sustained release and delayed
release with the coating materials Eudragit® EPO, Eudragit® RS/RL and Acryl-EZE,
respectively.
For the immediate release coating with Eudragit® EPO, the coating level presented no
influence on the drug release profiles due to the water-soluble property of Eudragit® EPO.
The results were ideal for immediate release coating.
For the sustained release coating with Eudragit® RS/RL, SEM micrographs indicated that
the pellets with higher coating level demonstrated better smoothness of the coating film.
From the in-vitro drug release tests, the cumulative release after 12 h decreased
dramatically as the coating level increased, indicating that the pellets with higher coating
level (17.88%) are able to sustain for a longer time (more than 12 h), since Eudragit®
RS/RL are water insoluble polymers and the drug release rate reduced with the increasing
coating film thickness. In addition, the mass ratio of the Eudragit® RS to Eudragit® RL
affected the drug release as well. The pellets with a higher ratio of the polymers
(Eudragit® RS/RL= 2:1) showed a slower release rate compared to the pellets with a
lower ratio (Eudragit® RS/RL=1:2). This is mainly because Eudragit® RS is less
permeable than Eudragit® RL since it has less amount of the quaternary ammonium
groups.
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For the Acryl-EZE coated pellets, the in-vitro drug release tests proved that the acid
resistance of the coated pellets in the first 2 h improved as the coating level increased.
The pellets with a coating level higher than 13.25% were qualified to achieve ‘delayed
release’ according to the USP <711> standard where the cumulative release should be
less than 10% after the 2 h release in acid medium.
Optimization of process conditions in RFB with dry powder coating technique was
investigated using Acryl-EZE as the example coating material. It was found that the RFB
should be operated under moderate conditions. The curing temperature has to be
maintained at 50 oC and the curing time should be no less than 2 h. This is because the
film formation of the coating materials can only be achieved with a curing step and the
curing temperature has to be closed to/above the Tg of the coating materials. In addition,
the most appropriate rotating speed of the RFB was around 20 rpm. Below the 20 rpm
range, the mixing of coating materials/pellets and the film formation were undesired.
Above that, the strong tumbling of the pellets possibly damaged the coating film.
Moreover, the most suitable plasticizer spraying rate and fluidizing air flowrate were
around 0.25 g/min and 35 L/min, respectively. The last three factors (RFB rotating speed,
plasticizer spraying rate and fluidizing air flow rate) should be matched with the pellets
loadings and coating material feedings, and may vary with the change of the RFB size.
The performance of the rotating pan coater and the traditional fluidized bed were studied
in comparison with the RFB. Acryl-EZE was selected as the example coating material.
Under similar operating conditions, the RFB demonstrated comparable coating efficiency
with the rotating pan coater while being superior to the fluidized bed. The latter is mainly
because the RFB required relatively small amount of fluidizing air than the traditional
fluidized bed that would not cause considerable loss of coating materials. In addition, the
RFB coated piroxicam pellets achieved continuous, dense and smooth coating film as
shown by the SEM micrographs, which were the same as the rotating pan coater and

93

much better than the fluidized bed. Furthermore, the RFB presented a potential ability of
the micronized pellets coating (0.1-0.03 mm) compared to the other two apparatus. This
is mainly owing to its unique closed system and the mild gasless fluidization generated
by the rotation and the introduced fluidizing air. The closed system prevents the
micronized pellets from being blown away and the fluidizing air helps the coating
materials form a uniform coating film.
In summary, dry powder coating of pharmaceutical pellets with the RFB is a promising
technique for the pharmaceutical coating industry. The coating of the pellets presented a
continuous and dense film with fast release, sustained release, delayed release
successfully modified. Compared to conventional aqueous coating, the operating time can
be efficiently shortened from hours even days to only 2-3 h and the operating temperature
is lowered as well. No organic solvent is required in contrast to the organic solvent
coating avoiding the potential hazards of the organic solvent evaporation.
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Appendix
Fast release
fast release
coating lvl=8.82

time/min cumulative
release
0
0
5
84.3559
10
97.9008
15
99.4754
20
99.5768
30
99.7905
45
100.0000
90
99.6667

release
coating lvl=19.9
date
20150629
error bar
time/min
cumulative
release
0
0
0
1.2562
5
71.0518
2.5543
10
89.3393
0.6640
15
94.0618
1.4027
20
95.9749
1.3686
30
97.9237
1.9495
45
97.5296
1.5689
60
99.5246
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release
date
20150223
error bar
0
4.1387
2.4997
1.8444
1.5740
1.3850
0.2083
0.7409

Sustained release
sustained release
RS:RL=2:1 release date
coating lvl=8.08%
time/h
cumulative
release
0
0
0.50
7.9078
1
32.0333
1.50
49.4109
2
63.8521
3.25
90.6562
4
93.7357
6
98.0565
8
99.4165
10
100
12
100

20150707

error bar
0
0.8271
4.1955
2.4314
1.6234
3.7107
2.4547
2.3934
0.8252
2.1236E-05
0

release
20150707
date
coating lvl=18.33%
time/h
cumulative
release
0
0
2
0
3.25
3.9321
4
8.6157
6
16.1381
8
28.2446
10
36.1675
12
37.8441
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error bar
0
0
1.2863
0.4636
2.9005
3.8930
4.2908
3.7238

RS:RL= release
1:1
date
coating lvl=9.23%

20150723

time/h

error bar

time/h

0
4.9687
6.5873
4.2476
3.2498
7.7329
7.3088
3.7099
0
0
0

0
0.5
1
2
4
6
8
10
12
16

0
0.5
1
2
2.5
3
3.5
4
6
8
12

cumulative
release
0
17.6045
37.7266
65.6735
79.3958
90.9481
95.6594
97.8581
100
100
100

release
20150723
date
coating lvl=13.13%
cumulative
release
0
2.4552
8.7879
16.8453
34.8817
51.4929
68.3035
77.8257
85.2255
100
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release date

error bar
0
0.4501
1.8849
1.3939
0.4419
1.3380
3.3165
1.0654
1.4303
0

coating
lvl=17.88%
time/h
0
0.5
1
2
3
4
6
8
10
12
24
26

20150805

cumulative
release
0
1.9567
2.9196
8.1449
11.4910
17.9959
26.5355
38.6567
50.0663
59.0139
98.6119
100

error bar
0
0.4324
0.6293
2.2477
1.9189
1.2183
1.1091
0.1807
3.5056
3.5801
1.0758
0

RS:RL= release date
1:2
coating lvl=8.83%

20150730

time/h

error bar

time/h

0
8.2867
2.5292
0.3400
0.8378
1.5094
0.3538
1.3561
0.0000
0
0
0

0
0.5
1
1.5
2
3
4
6
8
10
12
16

0
0.5
1
1.5
2
2.5
3
4
6
8
10
12

cumulative
release
0
47.5657
68.1650
80.3657
88.9337
93.4166
96.2532
98.5059
100.0000
100
100
100

release
20150730
date
coating lvl=13.99%
cumulative
release
0
0
4.5278
11.7631
17.7672
30.2681
39.9918
59.4250
74.5457
83.9905
90.4105
100
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release date

error bar

coating
lvl=17.55%
time/h

0
0
0.4447
1.2712
2.7193
3.3086
2.0175
2.0765
2.1576
1.7694
1.3409
0

0
0.5
1
2
3
4
6
8
10
12
24
26

20150805

cumulative
release
0
4.7158
5.5086
10.3782
17.4083
23.1458
35.9058
50.0904
61.6633
71.8944
99.1408
100

error bar
0
0.4670
1.2150
0.8740
1.1148
0.9466
0.1536
0.8895
2.0192
1.6190
1.4882
0

Delayed release
delayed release
coating lvl=10.84%

coating lvl=13.25%

release date

20150818

time/mi
n
0
30
60
90
120
140
150
180
210
240

error bar

average
release
0
5.0670
10.0001
13.8254
16.5748
92.1231
97.5977
98.1014
99.7231
100

0
1.1071
0.5263
1.0774
0.8278
2.0936
1.6210
0.9568
0.4796
0

release
date
time/min
0
30
60
90
120
130
140
150
180
210
240

average
release
0
1.3964
4.3002
6.5159
8.5870
92.9377
94.0250
98.5486
99.1051
99.4444
100
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20150821

coating
lvl=21.93%
release date

error bar

time/min

0
0.8294
1.4812
0.8961
0.7810
1.6242
0.8445
1.5278
1.1814
0.9510
0

0
30
60
90
120
130
140
150
180
210
240

20150619
average
release
0
2.5765
4.0477
5.3282
6.6573
94.0827
96.4472
98.0851
99.2156
99.5961
100

error bar
0
1.2455
1.3705
1.5077
1.4338
1.5077
1.3418
0.9253
0.2500
0.6997
0

Acryl-EZE, CL=14.6%, Temp=30 , speed=20rpm
Curing Time=1h
20150925
Curing Time=1.5h
time/mi
n
0
30
60
90
120
130
140
150
180
210
240

average
release
0
41.5338
63.2480
76.0246
85.2843
92.6046
100
100
100
100
100

error bar
0
0.2949
2.7458
0.8621
1.1918
1.6760
0
0
0
0
0

time/mi
n
0
30
60
90
120
130
140
150
180
210
240

20150925

average
release
0
35.4780
50.4859
61.9877
69.6619
90.4997
99.0933
100
100
100
100
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error bar

Curing
Time=2h
time/min

0
3.4935
4.0293
3.4341
2.7096
1.0241
1.2822
0
0
0
0

0
30
60
90
120
130
140
150
180
210
240

20150924
average
release
0
17.6270
22.6161
27.3274
30.9539
93.5742
99.9670
100
100
100
100

error bar
0
1.9756
2.9929
3.8709
4.8890
0.9248
0.0572
0
0
0
0

Acryl-EZE, CL=14%, Temp=40 , speed=20rpm
Curing Time=1h
20151029
Curing Time=1.5h
time/mi
n
0
30
60
90
120
130
140
150
180
210
240

average
release
0
13.128
19.217
23.810
28.580
93.379
97.430
98.697
99.677
100
100

error bar
0
2.534
2.706
2.588
2.034
2.519
0.846
1.523
0.560
0
0

time/mi
n
0
30
60
90
120
130
140
150
180
210
240

20151029

average
release
0
5.2614
14.4106
20.4025
24.0002
95.4454
96.5582
96.8588
100
100
100
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error bar

Curing
Time=2h
time/min

0
0.8283
2.9125
0.2695
4.3767
0.6299
0.6247
4.4423
0
0
0

0
30
60
90
120
130
140
150
180
210
240

20150930
average
release
0
3.8413
9.8087
11.6674
19.4309
85.6428
92.4422
99.0368
100
100
100

error bar
0
1.5514
3.8480
2.0208
2.9384
4.6927
3.6883
0.3621
0
0
0

Acryl-EZE, CL=14%, Temp=50 , Ratating speed=20rpm
Curing Time=1h
20151028 Curing Time=1.5h
time/mi
n
0
30
60
90
120
130
140
150
180
210
240

average
release
0
0
6.6084
11.6717
15.0641
94.9955
100
100
100
100
100

error bar
0
0
0.6320
0.7558
1.6503
5.1313
0
0
0
0
0

time/mi
n
0
30
60
90
120
130
140
150
180
210
240

20151028

average
release
0
0.4985
1.3401
7.4583
9.7111
88.4453
100
100
100
100
100
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error bar

Curing
Time=2h
time/min

0
0.7050
0.1672
0.0985
0.3925
2.4891
0
0
0
0
0

0
30
60
90
120
130
140
150
180
210
240

20150821
average
release
0
1.3964
4.3002
6.5159
8.5870
92.9377
94.0250
98.5486
99.1051
99.4444
100

error bar
0
0.8294
1.4812
0.8961
0.7810
1.6242
0.8445
1.5278
1.1814
0.9510
0

Acryl-EZE, CL=14%, Temp=50℃, Ratating speed=20rpm
Curing Time=1h
2015102 Curing Time=1.5h
8
time/mi average
error bar time/mi average
n
release
n
release
0
0
0
0
0
30
0
0
30
0.4985
60
6.6084
0.6320
60
1.3401
90
11.6717
0.7558
90
7.4583
120
15.0641
1.6503
120
9.7111
130
94.9955
5.1313
130
88.4453
140
100
0
140
100
150
100
0
150
100
180
100
0
180
100
210
100
0
210
100
240
100
0
240
100

20151028
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error bar

Curing
Time=2h
time/min

0
0.7050
0.1672
0.0985
0.3925
2.4891
0
0
0
0
0

0
30
60
90
120
130
140
150
180
210
240

average
release
0
1.3964
4.3002
6.5159
8.5870
92.9377
94.0250
98.5486
99.1051
99.4444
100

2015082
1
error bar
0
0.8294
1.4812
0.8961
0.7810
1.6242
0.8445
1.5278
1.1814
0.9510
0

Acryl-EZE coating lvl=14% Temp=50
,
curing time=2h, speed=6rpm
Curing Time=2h
20151105
time/min average release
error bar
0
0
0
30
10.2753
1.5848
60
18.0070
2.0321
90
24.6863
2.7766
120
29.7664
2.0080
130
92.3820
0.2319
140
96.8122
0.6654
150
99.5121
0.6900
180
100
0
210
100
0
240
100
0
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